<SEC-DOCUMENT>0000721371-22-000096.txt : 20220906
<SEC-HEADER>0000721371-22-000096.hdr.sgml : 20220906
<ACCEPTANCE-DATETIME>20220906065723
ACCESSION NUMBER:		0000721371-22-000096
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20220905
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220906
DATE AS OF CHANGE:		20220906

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CARDINAL HEALTH INC
		CENTRAL INDEX KEY:			0000721371
		STANDARD INDUSTRIAL CLASSIFICATION:	WHOLESALE-DRUGS PROPRIETARIES & DRUGGISTS' SUNDRIES [5122]
		IRS NUMBER:				310958666
		STATE OF INCORPORATION:			OH
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-11373
		FILM NUMBER:		221226825

	BUSINESS ADDRESS:	
		STREET 1:		7000 CARDINAL PLACE
		CITY:			DUBLIN
		STATE:			OH
		ZIP:			43017
		BUSINESS PHONE:		6147573033

	MAIL ADDRESS:	
		STREET 1:		7000 CARDINAL PLACE
		CITY:			DUBLIN
		STATE:			OH
		ZIP:			43017

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CARDINAL DISTRIBUTION INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>22-9-6cah8k.htm
<TEXT>
<XBRL>
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:cah="http://cardinalhealth.com/20220905" xmlns="http://www.w3.org/1999/xhtml">
  <head>
    <title></title>
    <!-- Licensed to: Wachtell, Lipton, Rosen & Katz
         Document created using Broadridge PROfile 22.7.2.5063
         Copyright 1995 - 2022 Broadridge -->
    <meta http-equiv="Content-Type" content="text/html" />
</head>

<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; background-color: #ffffff;">
<div id="DSPFiXBRLHidden" style="display: none;"><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" id="Fact_190409351da945fbbe65eee91acf4ccf" contextRef="c20220905to20220905" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" id="Fact_6a706bd7defc4405b0f6133a87afad33" contextRef="c20220905to20220905">0000721371</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="cah-20220905.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="c20220905to20220905"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-05</xbrli:startDate><xbrli:endDate>2022-09-05</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>

  <!--PROfilePageNumberReset%Num%1%%%-->
  <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 18pt; font-weight: bold;">
    <div style="text-align: left;">
      <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" /></div>
<div>
    UNITED STATES</div>
</div>

  <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 18pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>

  <div style="text-align: center; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-weight: bold;">WASHINGTON, D.C. 20549</div>

  <div style="text-align: center; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-weight: bold;">
    <hr style="height: inherit; width: 20%; color: #000000; background-color: #000000;" /></div>

  <div style="text-align: center; margin-top: 3pt; margin-bottom: 6pt; font-family: 'Times New Roman', Times, serif; font-size: 18pt; font-weight: bold;">FORM <ix:nonNumeric name="dei:DocumentType" id="Fact_fd6830dfec8d466d94d6582d40d505b6" contextRef="c20220905to20220905">8-K</ix:nonNumeric>
    <br />
  </div>

  <div style="text-align: center; margin-top: 3pt; margin-bottom: 6pt; font-family: 'Times New Roman', Times, serif; font-size: 18pt; font-weight: bold;">
    <hr style="height: inherit; width: 20%; color: #000000; background-color: #000000;" /> </div>

  <div style="text-align: center; margin-top: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-weight: bold;">CURRENT REPORT</div>

  <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-weight: bold;">Pursuant to Section 13 or 15(d) of the<span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br />
    </span>Securities Exchange Act of 1934</div>

  <div style="text-align: center; margin-top: 6pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-weight: bold;">Date of Report (Date of earliest event reported):&#160; <ix:nonNumeric name="dei:DocumentPeriodEndDate" id="Fact_8a316df863124678b5c83739c0585773" contextRef="c20220905to20220905" format="ixt:datemonthdayyearen">September 5, 2022</ix:nonNumeric></div>

  <div style="text-align: left; margin-top: 6pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold;">
    <hr style="height: inherit; width: 20%; color: #000000; background-color: #000000;" /></div>

  <div style="text-align: center; margin-top: 12pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><span style="font-size: 24pt;"><ix:nonNumeric name="dei:EntityRegistrantName" id="Fact_3df6f15f9bd74631b2d31c4c6ebb6171" contextRef="c20220905to20220905">Cardinal Health, Inc.</ix:nonNumeric></span><br />
    (Exact name of registrant as specified in its charter)<br />
  </div>

  <div style="text-align: center; margin-top: 12pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">
    <hr style="height: inherit; width: 20%; color: #000000; background-color: #000000;" /></div>

  <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 32.1%; vertical-align: bottom;">
          <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" id="Fact_c3b1d169ef414924b552b71fe310aa6c" contextRef="c20220905to20220905" format="ixt-sec:stateprovnameen">Ohio</ix:nonNumeric><br />
          </div>
        </td>

    <td style="width: 1.02%; vertical-align: bottom;">
          <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
        </td>

    <td style="width: 32.92%; vertical-align: bottom;">
          <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityFileNumber" id="Fact_2b284246a74a425383214deff041088f" contextRef="c20220905to20220905">1-11373</ix:nonNumeric><br />
          </div>
        </td>

    <td style="width: 1.02%; vertical-align: bottom;">
          <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
        </td>

    <td style="width: 32.94%; vertical-align: bottom;">
          <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" id="Fact_b311b2c4ae6c440ba28c85adeebaff6c" contextRef="c20220905to20220905">31-0958666</ix:nonNumeric><br />
          </div>
        </td>

  </tr>

  <tr>

    <td style="width: 32.1%; vertical-align: top;">
          <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">(State or Other Jurisdiction</div>
          <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">of Incorporation)</div>
        </td>

    <td style="width: 1.02%; vertical-align: bottom;">
          <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">&#160;</div>
        </td>

    <td style="width: 32.92%; vertical-align: top;">
          <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">(Commission</div>
          <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">File Number)</div>
        </td>

    <td style="width: 1.02%; vertical-align: bottom;">
          <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">&#160;</div>
        </td>

    <td style="width: 32.94%; vertical-align: top;">
          <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">(IRS Employer</div>
          <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">Identification No.)</div>
        </td>

  </tr>


</table>
  <div><br />
  </div>

  <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 100%; vertical-align: middle;">
          <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"> <br />
          </div>
          <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" id="Fact_3436f610b82a4d8abdfd0e826a4ea1a3" contextRef="c20220905to20220905">7000 Cardinal Place</ix:nonNumeric>,
            <ix:nonNumeric name="dei:EntityAddressCityOrTown" id="Fact_4d6b55d1e8a041f98e71cc4e7f36a307" contextRef="c20220905to20220905">Dublin</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="Fact_9aa7cb6ccba443469b38ecf4c6c9ee85" contextRef="c20220905to20220905" format="ixt-sec:stateprovnameen">Ohio</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" id="Fact_e0e5bf1a14194858af05ae9a3c41077d" contextRef="c20220905to20220905">43017</ix:nonNumeric></div>
          <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">(Address of Principal Executive Offices) (Zip Code)</div>
          <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"> <br />
          </div>
        </td>

  </tr>

  <tr>

    <td style="width: 100%; vertical-align: top;">
          <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(<ix:nonNumeric name="dei:CityAreaCode" id="Fact_4b357bf6dfbe41538e65aece1b403146" contextRef="c20220905to20220905">614</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" id="Fact_db9da761cb6841249ee987c40852f164" contextRef="c20220905to20220905">757-5000</ix:nonNumeric></div>
          <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">(Registrant&#8217;s telephone number, including area code)</div>
          <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"> <br />
          </div>
        </td>

  </tr>


</table>
  <div>
    <div style="margin-bottom: 12pt;">
      <hr style="height: inherit; width: 20%; color: #000000; background-color: #000000;" /></div>

    <div style="text-align: left; margin-bottom: 3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of
      the following provisions <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(see General Instruction A.2. below):</span></div>

  </div>

  <div style="text-align: left; margin-bottom: 3pt; text-indent: -9pt; margin-left: 9pt;"><ix:nonNumeric name="dei:WrittenCommunications" id="Fact_dc4667a2c441463ba5cba63cacedd55a" contextRef="c20220905to20220905" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><span style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">&#160;&#160;&#160;&#160; Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div>

  <div style="text-align: left; margin-bottom: 3pt;"><ix:nonNumeric name="dei:SolicitingMaterial" id="Fact_9011cd45df8f4d2b9f38cc3c690471b1" contextRef="c20220905to20220905" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><span style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">&#160;&#160;&#160;&#160; Soliciting
      material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div>

  <div style="text-align: left; margin-bottom: 3pt;"><ix:nonNumeric name="dei:PreCommencementTenderOffer" id="Fact_a486052835e54f8a938d1265b80704e8" contextRef="c20220905to20220905" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">&#160;&#160;&#160;&#160;
      Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div>

  <div style="text-align: left; margin-bottom: 6pt;"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" id="Fact_0bb0e6c2250c4c8c8a585c6c8df538b4" contextRef="c20220905to20220905" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">&#160;&#160;&#160;&#160;
      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div>

  <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Securities registered pursuant to Section 12(b) of the Act:</div>

  <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> <br />
  </div>

  <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36.61%; vertical-align: bottom;">
          <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Title of each class</div>
        </td>

    <td style="width: 39.1%; vertical-align: bottom;">
          <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Trading Symbol(s)</div>
        </td>

    <td style="width: 24.3%; vertical-align: bottom;">
          <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Name of each exchange on which registered</div>
        </td>

  </tr>

  <tr>

    <td style="width: 36.61%; vertical-align: top;">
          <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="dei:Security12bTitle" id="Fact_8335989fbb8c44b89d720c1f59ea144d" contextRef="c20220905to20220905">Common shares (without par value)</ix:nonNumeric><br />
          </div>
        </td>

    <td style="width: 39.1%; vertical-align: top;">
          <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="dei:TradingSymbol" id="Fact_23c697ef21c34b9f8f3b6020f745b3e3" contextRef="c20220905to20220905">CAH</ix:nonNumeric><br />
          </div>
        </td>

    <td style="width: 24.3%; vertical-align: top;">
          <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="dei:SecurityExchangeName" id="Fact_134357ea92c44f139950700ff0dcadf9" contextRef="c20220905to20220905" format="ixt-sec:exchnameen">New York Stock Exchange</ix:nonNumeric><br />
          </div>
        </td>

  </tr>


</table>
  <div style="text-align: left; margin-top: 6pt; margin-bottom: 6pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of
    1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</div>

  <div style="text-align: right; margin-bottom: 6pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" id="Fact_b58c59e76f0b42e6a1276c685540f93d" contextRef="c20220905to20220905" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric></div>

  <div style="text-align: left; margin-bottom: 6pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
    with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160; <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">&#9744;</span></div>

  <div style="text-align: left; margin-bottom: 6pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">
<div><br /></div>

    <hr style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" /></div>

  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; font-size: 12pt;" class="DSPFPageBreakArea">
    <div style="page-break-after:always;" class="DSPFPageBreak">
      <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

  </div>

  <div style="text-align: left; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item 1.01.&#160; Entry into a Material Definitive Agreement.</div>

  <div style="text-align: left; text-indent: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">On September 5, 2022, Cardinal Health, Inc. (the &#8220;Company&#8221;) entered into a Cooperation Agreement (the &#8220;Cooperation
    Agreement&#8221;) with Elliott Associates, L.P. and Elliott International, L.P. (together, &#8220;Elliott&#8221;). The Cooperation Agreement will remain effective until the later of (i) July 15, 2023 and (ii) 11:59&#160;p.m., Eastern Time, on the date that is five days
    following the date on which the Investor Designee (as defined below) or the Investor Designee&#8217;s successor ceases to serve on, or resigns from, the Company&#8217;s board of directors (the &#8220;Board&#8221;).</div>

  <div style="text-align: left; text-indent: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Pursuant to the Cooperation Agreement, the Company agreed, among other things, to appoint Steven K. Barg, Global Head of
    Engagement at Elliott (the &#8220;Investor Designee&#8221;), Michelle M. Brennan, Sujatha Chandrasekaran and Christine A. Mundkur as new independent members of the Board (collectively with the Investor Designee, the &#8220;New Directors&#8221;), effective as of September 6,
    2022. Each of the New Directors will be nominated by the Board to stand for election for a full term at the 2022 Annual Meeting of Shareholders (the &#8220;2022 Annual Meeting&#8221;). Following the departure of two directors (as discussed under Item 5.02 below),
    the size of the Board will be automatically decreased to 13 directors at the conclusion of the 2022 Annual Meeting.</div>

  <div style="text-align: left; text-indent: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In connection with the appointment of the New Directors, the Company also established an advisory Business Review
    Committee (the &#8220;Business Review Committee&#8221;) to address the matters contemplated by the Cooperation Agreement and the charter of the Business Review Committee. The Committee has three members: Jason M. Hollar, the Business Review Committee&#8217;s chair and
    the Chief Executive Officer of the Company, the Investor Designee and Akhil Johri. The Business Review Committee, with the assistance of the Company&#8217;s legal and financial advisors, will make recommendations to the full Board.</div>

  <div style="text-align: left; text-indent: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Pursuant to the Cooperation Agreement, Elliott has agreed to abide by certain standstill restrictions and voting
    commitments. The Cooperation Agreement also includes procedures regarding the replacement of any of the New Directors prior to the 2023 Annual Meeting of Shareholders and a mutual non-disparagement provision.</div>

  <div style="text-align: left; text-indent: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The Company&#8217;s obligations with respect to, among other things, the appointment of the New Directors, the nomination of
    the New Directors for election at the 2022 Annual Meeting, the replacement of a New Director upon departure from the Board and the formation of the Business Review Committee fall away in certain circumstances, including if Elliott has a net long
    position in the Company of less than 2.25%.</div>

  <div style="text-align: left; text-indent: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The foregoing summary of the Cooperation Agreement does not purport to be complete and is qualified in its entirety by
    reference to the full text of the Cooperation Agreement, including the initial Business Review Committee charter attached as an exhibit to the Cooperation Agreement, a copy of which is attached as Exhibit 10.1 and is incorporated by reference.</div>

  <div style="text-align: left; text-indent: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> <br />
  </div>

  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
    <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman',Times,serif; font-weight: normal; font-style: normal;" class="DSPFPageNumber">2</span></div>

    <div style="page-break-after: always;" class="DSPFPageBreak">
      <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

  </div>

  <div style="text-align: left; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item 5.02.&#160; Departure of Directors or Certain Officers&#894; Election of Directors&#894; Appointment of Certain Officers&#894;
    Compensatory Arrangements of Certain Officers.</div>

  <div style="text-align: left; text-indent: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The information set forth in Item 1.01 is incorporated herein by reference.</div>

  <div style="text-align: left; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Director Appointments</div>

  <div style="text-align: left; text-indent: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Pursuant to the Cooperation Agreement, each of the New Directors was appointed to the Board effective September 6, 2022.
    The Board has affirmatively determined that each of the New Directors is &#8220;independent&#8221; under the rules of the New York Stock Exchange and the rules and regulations of the U.S. Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;).</div>

  <div style="text-align: left; text-indent: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Each of the New Directors will receive compensation consistent with that received by the Company&#8217;s other non-employee
    directors, as described in the Company&#8217;s proxy statement on Schedule 14A for the 2021 Annual Meeting, filed with the U.S. Securities and Exchange Commission on September 23, 2021.</div>

  <div style="text-align: left; text-indent: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">There are no arrangements or understandings between any of the New Directors and any other person pursuant to which any
    of the New Directors was appointed as a director other than with respect to the matters referred to in Item 1.01. At this time, there are no transactions in which any of the New Directors has or will have an interest that would be required to be
    disclosed pursuant to Item 404(a) of Regulation S-K under the Exchange Act.</div>

  <div style="text-align: left; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Committee Composition</div>

  <div style="text-align: left; text-indent: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Effective as of September 6, 2022, the Board has reconstituted the Board&#8217;s standing committees as follows:</div>

  <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 21.05%; vertical-align: top;">
          <div>&#160;</div>
          <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="text-decoration: underline;">Audit Committee</span></div>
        </td>

    <td style="width: 30.7%; vertical-align: top;">
          <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> <br />
          </div>
          <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="text-decoration: underline;">Governance and Sustainability Committee</span></div>
        </td>

    <td style="width: 25.44%; vertical-align: top;">
          <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="text-decoration: underline;"> <br />
            </span></div>
          <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="text-decoration: underline;">Human Resources and Compensation Committee</span></div>
        </td>

    <td style="width: 22.81%; vertical-align: top;">
          <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> <br />
          </div>
          <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="text-decoration: underline;">Risk Oversight Committee</span></div>
        </td>

  </tr>

  <tr>

    <td style="width: 21.05%; vertical-align: top;">
          <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Akhil Johri (Chair)</div>
          <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Michelle M. Brennan</div>
          <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Sujatha Chandrasekaran</div>
          <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Sheri H. Edison</div>
          <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">David C. Evans</div>
          <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">John H. Weiland</div>
        </td>

    <td style="width: 30.7%; vertical-align: top;">
          <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Patricia A. Hemingway Hall (Chair)</div>
          <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Steven K. Barg</div>
          <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Carrie S. Cox</div>
          <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Bruce L. Downey</div>
          <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Gregory B. Kenny</div>
          <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Nancy Killefer</div>
        </td>

    <td style="width: 25.44%; vertical-align: top;">
          <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Carrie S. Cox (Chair)</div>
          <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Michelle M. Brennan</div>
          <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Patricia A. Hemingway Hall</div>
          <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Nancy Killefer</div>
          <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Christine A. Mundkur</div>
          <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Dean A. Scarborough</div>
        </td>

    <td style="width: 22.81%; vertical-align: top;">
          <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Sheri H. Edison (Chair)</div>
          <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Sujatha Chandrasekaran</div>
          <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Bruce L. Downey</div>
          <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">David C. Evans</div>
          <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Christine A. Mundkur</div>
          <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Dean A. Scarborough</div>
          <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">John H. Weiland</div>
        </td>

  </tr>


</table>
  <div style="margin-bottom: 12pt;"><br />
  </div>

  <div style="text-align: left; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Directors Not Standing for Re-election</div>

  <div style="text-align: left; text-indent: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">On September 6, 2022, the Company announced that Dean A. Scarborough and John H. Weiland have expressed their intent not
    to stand for re-election at the 2022 Annual Meeting.&#160; <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Messrs. Scarborough and Weiland will continue to serve as directors until the 2022 Annual Meeting.&#160; </span>The
    decisions of Messrs. Scarborough and Weiland were not due to any disagreements relating to matters concerning the Company&#8217;s operations, policies or practices, and the Board is greatly appreciative of Messrs. Scarborough&#8217;s and Weiland&#8217;s service and
    substantial contributions.</div>

  <div style="text-align: left; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item 7.01.&#160; Regulation FD Disclosure.</div>

  <div style="text-align: left; text-indent: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">On September 6, 2022, the Company issued a news release announcing the Company&#8217;s entry into the Cooperation Agreement
    and the matters described in Item 1.01 and Item 5.02.&#160; A copy of the news release is attached as Exhibit 99.1.</div>

  <div style="text-align: left; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item 9.01.&#160; Financial Statements and Exhibits.</div>

  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000; margin-bottom: 12pt;">


  <tr>

    <td style="width: 27pt;"><br />
        </td>

    <td style="width: 27pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(d)</td>

    <td style="width: auto; vertical-align: top; text-align: left;">
          <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Exhibits</div>
        </td>

  </tr>


</table>
  <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 14.42%; vertical-align: top; border-bottom: 2px solid #000000;">
          <div>
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Exhibit No.</div>
          </div>
        </td>

    <td style="width: 85.58%; vertical-align: top; border-bottom: 2px solid #000000;">
          <div>
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Description</div>
          </div>
        </td>

  </tr>

  <tr>

    <td style="width: 14.42%; vertical-align: top;">
          <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="exhibit10-1.htm">10.1</a></div>
        </td>

    <td style="width: 85.58%; vertical-align: top;">
          <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Cooperation Agreement, dated as of September 5, 2022, by and among Cardinal Health, Inc., Elliott Associates, L.P. and Elliott International, L.P.</div>
        </td>

  </tr>

  <tr>

    <td style="width: 14.42%; vertical-align: top;">
          <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="exhibit99-1pressrelease.htm">99.1</a></div>
        </td>

    <td style="width: 85.58%; vertical-align: top;">
          <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">News release issued by the Company on September 6, 2022 announcing governance enhancements and shareholder value creation initiatives.</div>
        </td>

  </tr>

  <tr>

    <td style="width: 14.42%; vertical-align: top;">
          <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">104</div>
        </td>

    <td style="width: 85.58%; vertical-align: top;">
          <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</div>
        </td>

  </tr>


</table>
  <div><br />
  </div>

  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; font-size: 12pt;" class="DSPFPageBreakArea">
    <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman',Times,serif; font-weight: normal; font-style: normal;" class="DSPFPageNumber">3</span></div>

    <div style="page-break-after:always;" class="DSPFPageBreak">
      <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

  </div>

  <div style="text-align: center; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">SIGNATURE</div>

  <div style="text-align: left; text-indent: 36pt; margin-bottom: 24pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be
    signed on its behalf by the undersigned hereunto duly authorized.</div>

  <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 50.5%; vertical-align: top;">
          <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Date:&#160; September&#160;6, 2022</div>
        </td>

    <td style="width: 49.5%; vertical-align: top;" colspan="2">
          <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Cardinal Health, Inc.</div>
          <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(Registrant)</div>
        </td>

  </tr>

  <tr>

    <td style="width: 50.5%; vertical-align: top;">
          <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
        </td>

    <td style="width: 4.04%; vertical-align: top;">
          <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
        </td>

    <td style="width: 45.46%; vertical-align: top;">
          <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
        </td>

  </tr>

  <tr>

    <td style="width: 50.5%; vertical-align: top;">
          <div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 1pt;">&#160;</div>
        </td>

    <td style="width: 4.04%; vertical-align: top;">
          <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">By:</div>
        </td>

    <td style="width: 45.46%; vertical-align: top; border-bottom: #000000 2px solid;">
          <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">/s/ Jessica L. Mayer</div>
        </td>

  </tr>

  <tr>

    <td style="width: 50.5%; vertical-align: top;">
          <div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 1pt;">&#160;</div>
        </td>

    <td style="width: 4.04%; vertical-align: top;">
          <div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 1pt;">&#160;</div>
        </td>

    <td style="width: 45.46%; vertical-align: top;">
          <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Name: Jessica L. Mayer</div>
        </td>

  </tr>

  <tr>

    <td style="width: 50.5%; vertical-align: top;">
          <div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 1pt;">&#160;</div>
        </td>

    <td style="width: 4.04%; vertical-align: top;">
          <div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 1pt;">&#160;</div>
        </td>

    <td style="width: 45.46%; vertical-align: top;">
          <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Title:&#160;&#160; Chief Legal and Compliance Officer</div>
        </td>

  </tr>


</table>
  <div><br />
  </div>

  <div style="text-align: center; font-size: 12pt;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman',Times,serif; font-weight: normal; font-style: normal;" class="DSPFPageNumber">4</span></div>

</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>exhibit10-1.htm
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Wachtell, Lipton, Rosen & Katz
         Document created using Broadridge PROfile 22.7.2.5063
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; text-align: right; color: rgb(0, 0, 0);">
  <!--PROfilePageNumberReset%Num%1%%%--> <font style="font-size: 12pt;"><u><font style="font-weight: bold;">EXHIBIT 10.1</font></u></font>
  <div><br>
  </div>
  <div style="text-align: left;">
    <div style="text-align: center; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-weight: bold;">COOPERATION AGREEMENT</div>
    <div style="text-align: justify; text-indent: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">This Cooperation Agreement (this &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Agreement</font>&#8221;), dated as of September 5, 2022, is by and among Elliott Associates, L.P., a Delaware limited partnership and Elliott International, L.P., a Cayman Islands limited partnership (each, an &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Elliott Party</font>,&#8221; and together, the &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Elliott Parties</font>&#8221;), and Cardinal
      Health, Inc., an Ohio corporation (the &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Company</font>&#8221;).&#160; In consideration of and reliance upon the mutual covenants and agreements contained in this
      Agreement, and for other good and valuable consideration, the receipt and sufficiency of which is acknowledged, the Elliott Parties and the Company agree as follows:</div>
    <div style="margin-bottom: 12pt; text-indent: 36pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">1.</font><font style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt">&#160;</font><font style="font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><u>New Directors; Business Review Committee</u>.</font></div>
    <div style="margin-bottom: 12pt; text-indent: 36pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">(a)</font><font style="display: inline-block; text-indent: 0px; font-size: 1px; width: 28.8pt">&#160;</font><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">New Director Appointments.</font>&#160; As promptly as practicable following the date
        of this Agreement, the Board of Directors of the Company (the &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Board</font>&#8221;) shall take such actions as are necessary to increase the size of the Board
        and appoint Steven Barg (the &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Investor Designee</font>&#8221;) Michelle Brennan, Sujatha Chandrasekaran, and Christine Mundkur (the &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">New Independent Directors</font>,&#8221; and together with the Investor Designee, the &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">New Directors</font>&#8221;) as new members of the Board.&#160; The Board will increase the size of the Board as necessary to enable the appointment of the New Directors in accordance with the Company&#8217;s Restated Code of Regulations (the &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Bylaws</font>&#8221;) and the Ohio General Corporation Law (the &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">OGCL</font>&#8221;).


        The Company agrees that from the Company&#8217;s 2022 Annual Meeting of Shareholders (the &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">2022 Annual Meeting</font>&#8221;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">)</font> until the Company&#8217;s 2023 Annual Meeting of Shareholders (the &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">2023 Annual
          Meeting</font>&#8221;), the size of the Board shall be no greater than thirteen (13) directors.</font></div>
    <div style="margin-bottom: 12pt; text-indent: 36pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">(b)</font><font style="display: inline-block; text-indent: 0px; font-size: 1px; width: 28.8pt">&#160;</font><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Nomination of New Directors.&#160; </font>The Company agrees that, provided that a
        New Director is able and willing to serve on the Board and, except with respect to Mr. Barg, continues to be a Qualified Director (as defined below):</font></div>
    <table cellspacing="0" cellpadding="0" border="0" id="4190a5f88077488daa414a3e7f8acf6e" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;">

        <tr>
          <td style="width: 12%; text-align: right;">
            <div><font style="font-size: 12pt;">&#160;(i)</font></div>
            <div><font style="font-size: 12pt;"> <br>
              </font></div>
            <div><font style="font-size: 12pt;"> <br>
              </font></div>
            <div><font style="font-size: 12pt;"> <br>
              </font></div>
          </td>
          <td style="width: 88%; font-size: 12pt;">
            <div>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; at the 2022 Annual Meeting, the Board will nominate such New Director, together with the other persons included in the Company&#8217;s slate of nominees for election as director at the 2022 Annual Meeting in accordance with this
              Section 1(b), as a director of the Company, with a term expiring at the 2023 Annual Meeting;</div>
            <div> <br>
            </div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;" id="9162c3e8c80c4e0aab07f109f6063765">

        <tr>
          <td style="width: 12%; text-align: right;">
            <div>&#160;<font style="font-size: 12pt;">(ii) <br>
              </font></div>
            <div><font style="font-size: 12pt;"> <br>
              </font></div>
          </td>
          <td style="width: 88%; font-size: 12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; the Board will recommend that the shareholders of the Company vote to elect such New Director as a director of the Company at the 2022 Annual Meeting; and<br>
          </td>
        </tr>

    </table>
    <font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"> </font></div>
  <div style="text-align: left;">
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;">

        <tr>
          <td style="width: 12%; text-align: right;">
            <div>&#160;<font style="font-size: 12pt;">(iii)</font></div>
            <div><font style="font-size: 12pt;"> <br>
              </font></div>
            <div><font style="font-size: 12pt;"> <br>
              </font></div>
            <div><font style="font-size: 12pt;"> <br>
              </font></div>
            <div><font style="font-size: 12pt;"> <br>
              </font></div>
          </td>
          <td style="width: 88%; font-size: 12pt;">
            <div> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; the Company will use its reasonable best efforts (which will include the solicitation of proxies) to obtain the election of such New Director at the 2022 Annual Meeting (for the avoidance of doubt, the Company will only be
              required to use substantially the same level of efforts and provide substantially the same level of support as is used and/or provided for the other director nominees of the Company with respect to the 2022 Annual Meeting).<br>
              <br>
            </div>
          </td>
        </tr>

    </table>
    <div style="margin-bottom: 12pt; text-indent: 36pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">(c)</font><font style="display: inline-block; text-indent: 0px; font-size: 1px; width: 28.8pt">&#160;</font><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">New Director Agreements, Arrangements and Understandings.&#160; </font>Each of the
        Elliott Parties agrees that neither it nor any of its Affiliates (as defined below) (a) will pay any compensation to any New Director (including any Successor Investor Designee (as defined below)) or other member of the Board or any officer
        regarding such person&#8217;s service to the Company, including on the Board or any committee thereof or (b) will have any agreement, arrangement or understanding, written or oral, with any New Director (including any Successor Investor Designee) or
        other member of the Board or any officer regarding such person&#8217;s service to the Company, including on the Board or any committee thereof (including pursuant to which such person will be compensated for his or her service to the Company, including
        as a director on, or nominee for election to, the Board or any committee thereof).&#160; The Company acknowledges that no Company Policy (as defined below) shall be violated by the Investor Designee receiving indemnification and/or reimbursement of
        expenses from the Elliott Parties or their respective Affiliates, <font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">provided</font> that the Investor Designee neither accepts nor receives compensation
        from the Elliott Parties or their respective Affiliates with respect to the Investor Designee&#8217;s service or action as a director of the Company.</font></div>
    <div style="margin-bottom: 12pt; text-indent: 36pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"> <br>
      </font></div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman', Times, serif; font-size: 11pt; font-weight: normal; font-style: normal;">1</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="margin-bottom: 12pt; text-indent: 36pt; text-align: left;">
      <div style="margin-bottom: 12pt; text-indent: 36pt;">
        <div style="text-align: left;">
          <div style="margin-bottom: 12pt; text-indent: 36pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">(d)</font><font style="display: inline-block; text-indent: 0px; font-size: 1px; width: 28.8pt">&#160;</font></div>
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;">

              <tr>
                <td style="width: 12%; text-align: right;">
                  <div><font style="font-size: 12pt;">&#160;(i)</font></div>
                  <div><font style="font-size: 12pt;"> <br>
                    </font></div>
                  <div><font style="font-size: 12pt;"> <br>
                    </font></div>
                  <div><font style="font-size: 12pt;"> <br>
                    </font></div>
                  <div><font style="font-size: 12pt;"> <br>
                    </font></div>
                  <div><font style="font-size: 12pt;"> <br>
                    </font></div>
                  <div><font style="font-size: 12pt;"> <br>
                    </font></div>
                  <div><font style="font-size: 12pt;"> <br>
                    </font></div>
                </td>
                <td style="width: 88%; font-size: 12pt;">
                  <div><font style="font-style: italic;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Successor Inventor Designee</font>. If the Investor Designee is unable or unwilling to serve as a director, resigns as a director, is removed as a director or ceases to be a director for
                    any other reason prior to the expiration of the Cooperation Period, the Elliott Parties and the Company will cooperate to select, and the Company will appoint, a substitute director mutually acceptable to the Company and the Elliott
                    Parties (the &#8220;Successor Investor Designee&#8221;) to serve as a director of the Company for the remainder of such Investor Designee&#8217;s term. Effective upon the appointment of the Successor Investor Designee to the Board, such Successor
                    Investor Designee will be considered the Investor Designee for all purposes of this Agreement.<br>
                  </div>
                  <div> <br>
                  </div>
                </td>
              </tr>

          </table>
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;">

              <tr>
                <td style="width: 12%; text-align: right;">
                  <div><font style="font-size: 12pt;">&#160;<font style="font-size: 12pt;">(ii) </font><br>
                    </font></div>
                  <div><font style="font-size: 12pt;"> <br>
                    </font></div>
                  <div><font style="font-size: 12pt;"> <br>
                    </font></div>
                  <div><font style="font-size: 12pt;"> <br>
                    </font></div>
                  <div><font style="font-size: 12pt;"> <br>
                    </font></div>
                  <div><font style="font-size: 12pt;"> <br>
                    </font></div>
                  <div><br>
                    <br>
                    </div>
                  <div><font style="font-size: 12pt;"> <br>
                    </font></div>
                </td>
                <td style="width: 88%; font-size: 12pt;"><font style="font-style: italic;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Replacement New Independent Directors</font>. If any New Independent Director is unable or unwilling to serve as a director, resigns as a director, is
                  removed as a director or ceases to be a director for any other reason prior to the 2023 Annual Meeting, and at such time the Elliott Parties beneficially own at least the Minimum Ownership Threshold (as defined below), the Elliott Parties
                  and the Company will cooperate in good faith to select, as promptly as practicable, and the Company will appoint, a substitute director mutually acceptable to the Company and the Elliott Parties (the &#8220;Replacement New Independent
                  Director&#8221;) to serve as a director of the Company for the remainder of the New Independent Director&#8217;s term. Effective upon the appointment of the Replacement New Independent Director to the Board, such Replacement New Independent Director
                  will be considered a New Independent Director for all purposes of this Agreement.<br>
                </td>
              </tr>

          </table>
          </div>
      </div>
    </div>

    <div style="margin-bottom: 12pt; text-indent: 36pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">(e)</font><font style="display: inline-block; text-indent: 0px; font-size: 1px; width: 28.8pt">&#160;</font><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">New Director Information.&#160; </font>As a condition to a New Director&#8217;s
        appointment to the Board and any subsequent nomination for election as a director at any future Company annual meeting of shareholders, a New Director will provide any information the Company reasonably requires, including information required to
        be disclosed in a proxy statement or other filing under applicable law, stock exchange rules or listing standards, information in connection with assessing eligibility, independence and other criteria applicable to directors or satisfying
        compliance and legal obligations, and will consent to appropriate background checks, to the extent, in each case, consistent with the information and background checks required by the Company in accordance with past practice with respect to other
        members of the Board.</font></div>
    <div style="margin-bottom: 12pt; text-indent: 36pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">(f)</font><font style="display: inline-block; text-indent: 0px; font-size: 1px; width: 28.8pt">&#160;</font><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Business Review Committee</font>.&#160; As soon as reasonably possible following the
        appointment of the New Directors, the Board shall take all action necessary to form an advisory Business Review Committee of the Board (the &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Committee</font>&#8221;)


        heading into the Investor Day (as defined below) to support the Board and management&#8217;s reviews of the matters set forth in the Committee&#8217;s charter.&#160; The Board shall cause the Committee to be composed of three members, including the Company&#8217;s Chief
        Executive Officer, who shall serve as Chairman of the Committee, Mr. Barg, and one other director who is Independent as determined by the Board.&#160; If Mr. Barg or any Successor Investor Designee is unable or unwilling to serve as a member of the
        Committee, resigns as a member, is removed as a member or ceases to be a member for any other reason prior to the Investor Day, the Elliott Parties shall be entitled to select, in consultation with the Company and as approved by the Board (such
        approval not to be unreasonably withheld, conditioned or delayed), another New Director serving on the Board at the time of such selection to serve on the Committee as a replacement for such member (the &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Replacement Committee Member</font>&#8221;), provided that such Company consultation and Board approval shall not be required for a Successor Investor Designee selected by the Elliott Parties to
        serve as a Replacement Committee Member for Mr. Barg. The initial charter of the Committee shall be in the form attached to this Agreement as <font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Exhibit B</u></font> (the
        &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Committee Charter</font>&#8221;), and shall not be modified prior to the Investor Day except with the written consent of the Elliott Parties (such consent
        not to be unreasonably withheld, conditioned or delayed).&#160; The Company agrees that the Committee shall continue in existence until the completion of the Investor Day, or such later date as may be determined by the Chairman of the Committee
        following consultation with the Board.</font></div>
    <div style="margin-bottom: 12pt; text-indent: 36pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"> <br>
      </font></div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman', Times, serif; font-size: 11pt; font-weight: normal; font-style: normal;">2</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="margin-bottom: 12pt; text-indent: 36pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">(g)</font><font style="display: inline-block; text-indent: 0px; font-size: 1px; width: 28.8pt">&#160;</font><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Investor Day</font>. On or prior to June 30, 2023, the Company shall hold an
        investor day (the &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Investor Day</font>&#8221;), consistent with the Press Release and as contemplated by the Committee Charter.</font></div>
    <div style="margin-bottom: 12pt; text-indent: 36pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">(h)</font><font style="display: inline-block; text-indent: 0px; font-size: 1px; width: 28.8pt">&#160;</font><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Investor Designee Committee Membership.</font> As soon as reasonably possible
        following the appointment of the New Directors to the Board, the Board shall appoint Mr. Barg to the Board&#8217;s Governance and Sustainability Committee.</font></div>
    <div style="margin-bottom: 12pt; text-indent: 36pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">(i)</font><font style="display: inline-block; text-indent: 0px; font-size: 1px; width: 28.8pt">&#160;</font><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Company Policies.&#160; </font>The parties acknowledge that each of the New
        Directors, upon appointment to the Board, will be governed by the same protections and obligations regarding confidentiality, conflicts of interest, related party transactions, fiduciary duties, codes of conduct, trading and disclosure policies,
        director resignation policy, and other governance guidelines and policies of the Company as other directors of the Company (collectively, &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Company
          Policies</font>&#8221;), and shall have the same rights and benefits, including with respect to insurance, indemnification, compensation and fees, as are applicable to all independent directors of the Company. The Company acknowledges that the Company
        Policies do not apply to the Elliott Parties and their Affiliates, including Company Policies with respect to trading in the Company&#8217;s securities, as they are not directors or employees of the Company.</font></div>
    <div style="margin-bottom: 12pt; text-indent: 36pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">(j)</font><font style="display: inline-block; text-indent: 0px; font-size: 1px; width: 28.8pt">&#160;</font><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Limitation of Appointment Right; Termination.</font>&#160; The Company&#8217;s obligations
        under this Section 1 shall terminate, and the Elliott Parties shall have no designation or nomination or other rights under this Section 1, upon the earlier of:&#160; (i) such time as the Elliott Parties beneficially own less than a &#8220;net long position&#8221;
        of at least 2.25% (the &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Minimum Ownership Threshold</font>&#8221;) of the then outstanding Company Common Shares (as defined below), (ii) such time as any
        Elliott Party or other Restricted Person (as defined below) breaches in any material respect any of the terms of this Agreement (including Section 2), (iii) such time as Mr. Barg (or a Successor Investor Designee) notifies the Company of his intent
        to resign from the Board and the Elliott Parties irrevocably waive in writing any right to have a Successor Investor Designee appointed, or (iv) any member of the Elliott Group or any other Restricted Person submits any director nominations for
        election at any meeting of the Company&#8217;s shareholders. Upon the occurrence of an event described in clause (iv) of the previous sentence, if Mr. Barg (or a Successor Investor Designee) is on the Board, he shall promptly offer to resign from the
        Board (and, if requested by the Company, promptly deliver his written resignation to the Board for his immediate resignation, it being understood that it shall be in the Board&#8217;s sole discretion whether to accept or reject such resignation).&#160; The
        Elliott Parties agree to cause, and agree to cause their respective Affiliates to cause, Mr. Barg(or a Successor Investor Designee)&#160; to resign from the Board if he fails to resign if and when requested pursuant to this Section 1(i).</font></div>
    <div style="margin-bottom: 12pt; text-indent: 36pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"> <br>
      </font></div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman', Times, serif; font-size: 11pt; font-weight: normal; font-style: normal;">3</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="margin-bottom: 12pt; text-indent: 36pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">2.</font><font style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt">&#160;</font><font style="font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><u>Cooperation</u>.</font></div>
    <div style="margin-bottom: 12pt; text-indent: 36pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">(a)</font><font style="display: inline-block; text-indent: 0px; font-size: 1px; width: 28.8pt">&#160;</font><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Non-Disparagement.&#160; </font>Each of the Elliott Parties and the Company agrees
        that, from the date of this Agreement until the latest of (x) July 15, 2023, and (y) the Expiration Time (as defined below)&#160; (such period, the &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Cooperation


          Period</font>&#8221;), the Company, each Elliott Party and Mr. Barg shall refrain from making, and shall cause their respective controlling and controlled (and under common control) Affiliates and its and their respective principals, directors,
        members, general partners, officers, and employees not to make or cause to be made any public statement or announcement (or any statement or announcement that can reasonably be expected to become public) that constitutes an ad hominem attack on, or
        that otherwise disparages, defames, slanders, impugns or otherwise damages the reputation of (A)&#160;in the case of any such statements or announcements by any of the Elliott Parties, Mr. Barg or their related parties, the Company and its Affiliates or
        any of its or their current or former officers, directors, or employees, and (B)&#160;in the case of any such statements or announcements by the Company or <font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">its </font>related
        parties, the Elliott Parties and their Affiliates or any of their current or former principals, directors, members, general partners, officers, or employees, in each case including (x)&#160;in any statement (oral or written), document, or report filed
        with, furnished, or otherwise provided to the SEC (as defined below) or any other governmental agency, (y)&#160;in any press release or other publicly available format, or (z)&#160;to any journalist or member of the media (including, in a television, radio,
        newspaper, or magazine interview or Internet or social media communication). The<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"> foregoing</font> shall not (x)&#160;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">restrict the ability of any person to comply with any subpoena or other legal process or respond to a request for information from any governmental authority with jurisdiction over the party from whom information is sought
          or to enforce such person&#8217;s rights hereunder or (y)&#160;apply to any private communications among </font>the Elliott Parties and their Affiliates and Representatives (in their capacity as such)<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">, on the one hand, and among </font>the Company and <font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">its </font>Affiliates and Representatives (in their capacity as such)<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">, on the other hand</font>.</font></div>
    <div style="margin-bottom: 12pt; text-indent: 36pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">(b)</font><font style="display: inline-block; text-indent: 0px; font-size: 1px; width: 28.8pt">&#160;</font><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Voting of the Elliott Parties&#8217; Shares.&#160; </font>During the Cooperation Period,
        each Elliott Party (including Mr. Barg) will cause all of the outstanding common shares (without par value) of the Company (&#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Company Common Shares</font>&#8221;)


        that such Elliott Party or any of its controlling or controlled Affiliates has the right to vote (or to direct the vote) as of the applicable record date, to be present in person or by proxy for quorum purposes and to be voted at any meeting of
        shareholders of the Company or at any adjournments or postponements thereof, and to consent in connection with any action by written consent in lieu of a meeting, (w) in favor of each director nominated and recommended by the Board for election at
        the 2022 Annual Meeting, or, if applicable, any other meeting of shareholders of the Company during the Cooperation Period, (x) against any shareholder nominations for director that are not approved and recommended by the Board for election at any
        such meeting or through any such written consent, (y) against any proposals or resolutions to remove any member of the Board and (z) in accordance with recommendations by the Board on all other proposals or business that may be the subject of
        shareholder action at such meetings or written consents; provided, however, that the Elliott Parties shall be permitted to vote in their sole discretion on proposals related to any Extraordinary Transaction (as defined below); provided, further,
        that in the event that both Institutional Shareholder Services and Glass Lewis &amp; Co. (including any successors thereof) issues a voting recommendation that differs from the voting recommendation of the Board with respect to any
        Company-sponsored proposal submitted to shareholders at a shareholder meeting (other than with respect to the election of directors to the Board, the removal of directors from the Board, the size of the Board and the filling of vacancies on the
        Board), the Elliott Parties shall be permitted to vote in accordance with any such recommendation.</font></div>
    <div style="margin-bottom: 12pt; text-indent: 36pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"> <br>
      </font></div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman', Times, serif; font-size: 11pt; font-weight: normal; font-style: normal;">4</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="margin-bottom: 12pt; text-indent: 36pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">(c)</font><font style="display: inline-block; text-indent: 0px; font-size: 1px; width: 28.8pt">&#160;</font><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Standstill.&#160; </font>During the Cooperation Period, each Elliott Party will not,
        and will cause its controlling and controlled (and under common control) Affiliates and its and their respective Representatives acting on their behalf (collectively with the Elliott Parties, the &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Restricted Persons</font>&#8221;) to not, directly or indirectly, without the prior written consent, invitation, or authorization of or by the Company or the Board:</font></div>
    <div>
      <table cellspacing="0" cellpadding="0" id="zf90e85a85f6c487684db24b4aedec0b5" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 12%; vertical-align: top;">
              <div style="text-align: right; margin-left: 64.8pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif; font-size: 12pt;">(i)</div>
            </td>
            <td style="width: 88%; vertical-align: top; font-size: 12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; acquire, or offer or agree to acquire, by purchase or otherwise, or direct any third party in the acquisition of, record or beneficial ownership of any securities of the
              Company or rights or options to acquire any securities of the Company, or engage in any swap or hedging transactions or other derivative agreements of any nature with respect to any securities of the Company, in each case, if such
              acquisition, offer, agreement or transaction would result in the Elliott Parties (together with their Affiliates) having beneficial ownership of more than 7.5% or aggregate economic exposure to more than 9.9% of the Company Common Shares
              outstanding at such time;<br>
            </td>
          </tr>

      </table>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;" id="f9ede859caa24554891632eff28b05b4" class="DSPFListTable">

        <tr>
          <td style="width: 12%; vertical-align: top;">
            <div style="text-align: right; margin-left: 64.8pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif; font-size: 12pt;">(ii)</div>
          </td>
          <td style="width: 88%; vertical-align: top; font-size: 12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (A) call or seek to call (publicly or otherwise), alone or in concert with others, a meeting of the Company&#8217;s shareholders or action by written consent (or the setting of a
            record date therefor), (B) seek, alone or in concert with others, election or appointment to, or representation on, the Board or nominate or propose the nomination of, or recommend the nomination of, any candidate to the Board, except as
            expressly set forth in Section 1, (C) make or be the proponent of any shareholder proposal to the Company or the Board or any committee thereof, (D) seek, alone or in concert with others (including through any &#8220;withhold&#8221; or similar campaign),
            the removal of any member of the Board, or (E) conduct a referendum of shareholders of the Company; provided that nothing in this Agreement will prevent the Elliott Parties or their Affiliates from taking actions in furtherance of identifying
            any Successor Investor Designee or director candidate in connection with the Company&#8217;s 2023 Annual Meeting of Shareholders;<br>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;" id="650ab4949a18450c814fe96912b4501b" class="DSPFListTable">

        <tr>
          <td style="width: 12%; vertical-align: top;">
            <div style="text-align: right; margin-left: 64.8pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif; font-size: 12pt;">(iii)</div>
          </td>
          <td style="width: 88%; vertical-align: top; font-size: 12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; make any request for stock list materials or other books and records of the Company or any of its subsidiaries under the OGCL or other statutory or regulatory provisions
            providing for shareholder access to books and records;<br>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;" id="47b2ec3b47ba427d89d2d1e39054c198" class="DSPFListTable">

        <tr>
          <td style="width: 12%; vertical-align: top;">
            <div style="text-align: right; margin-left: 64.8pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif; font-size: 12pt;">(iv)</div>
          </td>
          <td style="width: 88%; vertical-align: top; font-size: 12pt;">
            <div>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; engage in any &#8220;solicitation&#8221; (as such term is used in the proxy rules of the SEC excluding, for the avoidance of doubt, carve-outs relating to solicitations of ten or fewer shareholders) of proxies or consents with respect to the
              election or removal of directors of the Company or any other matter or proposal relating to the Company or become a &#8220;participant&#8221; (as such term is used in the proxy rules of the SEC) in any such solicitation of proxies or consents;<br>
            </div>
            <div> <br>
            </div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;" id="3c0bebcc8be946089f01046326d17345" class="DSPFListTable">

        <tr>
          <td style="width: 12%; vertical-align: top;">
            <div style="text-align: right; margin-left: 64.8pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif; font-size: 12pt;">(v)</div>
          </td>
          <td style="width: 88%; vertical-align: top; font-size: 12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; make or submit any proposal for, or offer of (with or without conditions), either alone or in concert with others, any tender offer, exchange offer, merger, amalgamation,
            consolidation, acquisition, business combination, recapitalization, restructuring, liquidation, dissolution or similar extraordinary transaction involving the Company (including its subsidiaries and joint ventures or any of their respective
            securities or assets) (each, an &#8220;<font style="font-weight: bold;">Extraordinary Transaction</font>&#8221;) either publicly or in a manner that would reasonably be expected to require public disclosure by the Company or any of the Elliott Parties (it
            being understood that the foregoing shall not restrict the Restricted Persons from tendering shares, receiving payment for shares or otherwise participating in any Extraordinary Transaction on the same basis as other shareholders of the
            Company); <br>
          </td>
        </tr>

    </table>
  </div>
  <div style="text-align: left;"> <br>
  </div>
  <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman', Times, serif; font-size: 11pt; font-weight: normal; font-style: normal;">5</font></div>
    <div id="DSPFPageBreak" style="page-break-after: always;">
      <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
  </div>
  <div style="text-align: left;">
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;" id="8bd13c666233471abaf07777ee8021d8" class="DSPFListTable">

        <tr>
          <td style="width: 12%; vertical-align: top;">
            <div style="text-align: right; margin-left: 64.8pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif; font-size: 12pt;">(vi)</div>
          </td>
          <td style="width: 88%; vertical-align: top; font-size: 12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; make any public proposal with respect to (A) any change in the number or identity of directors or the filling of any vacancies on the Board other than as provided under
            Section 1 of this Agreement, (B) any change in the capitalization, capital allocation policy or dividend policy of the Company, (C) any other change in the Company&#8217;s management or corporate structure, (D) any waiver, amendment or modification
            to the Company&#8217;s Articles of Incorporation or the Bylaws (collectively, the &#8220;<font style="font-weight: bold;">Organizational Documents</font>&#8221;), (E) causing a class of securities of the Company to be delisted from, or to cease to be authorized
            to be quoted on, any securities exchange or (F) causing a class of securities of the Company to become eligible for termination of registration pursuant to Section 12(g)(4) of the Exchange Act (as defined below);<br>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;" id="7e41898e810547bd9413719e55b639fd" class="DSPFListTable">

        <tr>
          <td style="width: 12%; vertical-align: top;">
            <div style="text-align: right; margin-left: 64.8pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif; font-size: 12pt;">(vii)</div>
          </td>
          <td style="width: 88%; vertical-align: top; font-size: 12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; knowingly encourage or advise any third party or knowingly assist any third party in encouraging or advising any other person (A) with respect to the giving or withholding of
            any proxy or consent relating to, or other authority to vote, any securities of the Company, or (B) in conducting any type of referendum relating to the Company (other than such encouragement or advice that is consistent with the Board&#8217;s
            recommendation in connection with such matter, or as otherwise specifically permitted under this Agreement);<br>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;" id="344b4d6627424f8696a4c7d304a7b66f" class="DSPFListTable">

        <tr>
          <td style="width: 12%; vertical-align: top;">
            <div style="text-align: right; margin-left: 64.8pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif; font-size: 12pt;">(viii)</div>
          </td>
          <td style="width: 88%; vertical-align: top; font-size: 12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; form, join or act in concert with any &#8220;group&#8221; as defined in Section 13(d)(3) of the Exchange Act, with respect to any securities of the Company, other than solely with
            Affiliates of the Elliott Parties with respect to any securities of the Company now or hereafter owned by them;<br>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;" id="116c903d51cc49c991ced56434705278" class="DSPFListTable">

        <tr>
          <td style="width: 12%; vertical-align: top;">
            <div style="text-align: right; margin-left: 64.8pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif; font-size: 12pt;">(ix)</div>
          </td>
          <td style="width: 88%; vertical-align: top; font-size: 12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; enter into a voting trust, arrangement or agreement, or subject any securities of the Company to any voting trust, arrangement or agreement (excluding customary brokerage
            accounts, margin accounts, prime brokerage accounts and the like), in each case other than (A) this Agreement, (B) solely with Affiliates of the Elliott Parties or (C) granting proxies in solicitations approved by the Board;</td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;" id="f19ae7b3eeaa475283fb1e76bd183730" class="DSPFListTable">

        <tr>
          <td style="width: 12%; vertical-align: top;">
            <div style="text-align: right; margin-left: 64.8pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif; font-size: 12pt;">(x)</div>
          </td>
          <td style="width: 88%; vertical-align: top; font-size: 12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; engage in any short sale or any purchase, sale, or grant of any option, warrant, convertible security, stock appreciation right, or other similar right (including any put or
            call option or &#8220;swap&#8221; transaction) with respect to any security (other than any index fund, exchange traded fund, benchmark fund or broad basket of securities) that includes, relates to, or derives any significant part of its value from a
            decline in the market price or value of the securities of the Company and would, in the aggregate or individually, result in the Elliott Parties ceasing to have a &#8220;net long position&#8221; in the Company;</td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;" id="7055d25db00845829ac9b3557f1e1777" class="DSPFListTable">

        <tr>
          <td style="width: 12%; vertical-align: top;">
            <div style="text-align: right; margin-left: 64.8pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif; font-size: 12pt;">(xi)</div>
          </td>
          <td style="width: 88%; vertical-align: top; font-size: 12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; sell, offer or agree to sell, all or substantially all, directly or indirectly, through swap or hedging transactions or otherwise, voting rights decoupled from the underlying
            Company Common Shares held by a Restricted Person to any third party;<br>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;" id="88a3299838fe4383aff39c95a1deebcf" class="DSPFListTable">

        <tr>
          <td style="width: 12%; vertical-align: top;">
            <div style="text-align: right; margin-left: 64.8pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif; font-size: 12pt;">(xii)</div>
          </td>
          <td style="width: 88%; vertical-align: top; font-size: 12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; institute, solicit or join, as a party, any litigation, arbitration, or other proceeding against or involving the Company, its Affiliates or any of its or their respective
            current or former directors or officers (including derivative actions)&#894; provided, however, that for the avoidance of doubt, the foregoing shall not prevent any Restricted Person from (A) bringing litigation against the Company to enforce any
            provision of this Agreement instituted in accordance with and subject to Section 11, (B) making counterclaims with respect to any proceeding initiated by, or on behalf of, the Company or its Affiliates against a Restricted Person, (C) bringing
            bona fide commercial disputes that do not relate to the subject matter of this Agreement, (D) exercising any statutory appraisal rights, or (E) responding to or complying with a validly issued legal process;<br>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;" id="002380e2bc18455e802f64dce63aceb5" class="DSPFListTable">

        <tr>
          <td style="width: 12%; vertical-align: top;">
            <div style="text-align: right; margin-left: 64.8pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif; font-size: 12pt;">(xiii)</div>
          </td>
          <td style="width: 88%; vertical-align: top; font-size: 12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; enter into any negotiations, agreements (whether written or oral), arrangements, or understandings with any third party to take any action that the Restricted Persons are
            prohibited from taking pursuant to this Section 2(c); or</td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;" id="11a7f341bfdc4f57835886e4a5bbbb8a" class="DSPFListTable">

        <tr>
          <td style="width: 12%; vertical-align: top;">
            <div style="text-align: right; margin-left: 64.8pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif; font-size: 12pt;">(xiv)</div>
          </td>
          <td style="width: 88%; vertical-align: top; font-size: 12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; make any request or submit any proposal to amend or waive the terms of this Agreement (including this subclause), in each case publicly or which would reasonably be expected
            to result in a public announcement or disclosure of such request or proposal by the Company or any of the Restricted Persons;</td>
        </tr>

    </table>
    <div style="text-align: justify; margin-left: 18pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"> <br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman', Times, serif; font-size: 11pt; font-weight: normal; font-style: normal;">6</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; margin-left: 18pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">provided, that the restrictions in this Section 2(c) shall terminate automatically upon the earliest of the
      following: (i)&#160;any material breach of this Agreement by the Company (including, without limitation, a failure to appoint the New Directors to the Board or the Committee in accordance with Section 1, a failure to form the Committee, or a failure to
      issue the Press Release in accordance with Section 3) upon five (5) business days&#8217; written notice by any of the Elliott Parties to the Company if such breach has not been cured within such notice period, provided that the Elliott Parties are not in
      material breach of this Agreement at the time such notice is given or prior to the end of the notice period; (ii)&#160;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">the Company&#8217;s (x)&#160;entry into a definitive agreement with
        respect to any Extraordinary Transaction that would result in the acquisition by any person or group of more than 50% of the Company Common Shares or assets having an aggregate value exceeding 50% of the aggregate enterprise value of the Company,
        or (y)&#160;entry into one or more definitive agreements providing for a transaction or series of related transactions which would in the aggregate result in the Company issuing to one or more third parties at least 10% of the Company Common Shares
        (including on an as-converted basis) outstanding immediately prior to such issuance(s) (including in a PIPE, convertible note, convertible preferred security or similar structure) during the Cooperation Period (provided that securities issued as
        consideration for (or in connection with) the acquisition of the assets, securities and/or business(es) of another person by the Company or one or more of its subsidiaries shall not be counted toward this clause (y));</font> and (iii)&#160;the
      commencement of any tender or exchange offer (by any person or group other than the Elliott Parties or their Affiliates) which, if consummated, would constitute an Extraordinary Transaction that would result in the acquisition by any person or group
      of more than 50% of the Company Common Shares, where the Company files with the SEC a Schedule 14D-9 (or amendment thereto) that does not recommend that its shareholders reject such tender or exchange offer (it being understood that nothing herein
      will prevent the Company from issuing a &#8220;stop, look and listen&#8221; communication pursuant to Rule 14d-9(f) promulgated under the Exchange Act in response to the commencement of any tender or exchange offer).&#160; Notwithstanding anything to the contrary in
      this Agreement, nothing in this Agreement (including but not limited to the restrictions in this Section 2(c)) will prohibit or restrict any of the Restricted Persons from (A)&#160;making any public or private statement or announcement with respect to any
      Extraordinary Transaction that is publicly announced by the Company or a third party, (B)&#160;making any factual statement to comply with any subpoena or other legal process or respond to a request for information from any governmental authority with
      jurisdiction over such person from whom information is sought (so long as such process or request did not arise as a result of discretionary acts by any Restricted Person), (C)&#160;granting any liens or encumbrances on any claims or interests in favor of
      a bank or broker-dealer or prime broker holding such claims or interests in custody or prime brokerage in the ordinary course of business, which lien or encumbrance is released upon the transfer of such claims or interests in accordance with the
      terms of the custody or prime brokerage agreement(s), as applicable, (D)&#160;negotiating, evaluating and/or trading, directly or indirectly, in any index fund, exchange traded fund, benchmark fund or broad basket of securities which may contain or
      otherwise reflect the performance of, but not primarily consist of, securities of the Company or (E)&#160;providing its views privately to the Board or the Company&#8217;s Chief Executive Officer, Chief Financial Officer, General Counsel, Head of Investor
      Relations and financial or legal advisors that have been identified by one of the foregoing to the Elliott Parties as appropriate contacts and, to the extent that such communication is approved in writing in advance by the Company&#8217;s General Counsel,
      other personnel of the Company, so long as such communications would not reasonably be expected to require any public disclosure of such communications or the content thereof, regarding any matter, or privately requesting a waiver of any provision of
      this Agreement, as long as such private communications or requests would not reasonably be expected to require public disclosure of such communications or requests by the Company or any of the Restricted Persons. Furthermore, nothing in this
      Agreement shall prohibit or restrict the Investor Designee in his or her personal capacity as a director from exercising his or her rights and fiduciary duties as a director of the Company or restrict his or her discussions solely among other members
      of the Board and/or management, advisors, Representatives or agents of the Company; provided that any such discussions are limited to communications in his or her personal capacity as a director.</div>
    <div style="text-align: justify; margin-left: 18pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"> <br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman', Times, serif; font-size: 11pt; font-weight: normal; font-style: normal;">7</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="margin-bottom: 12pt; text-indent: 36pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">3.</font><font style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt">&#160;</font><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Public Announcement</u>.&#160; Not later than 8:30 a.m. Eastern Time on September 6, 2022, the Company
          shall issue a press release in the form attached to this Agreement as Exhibit A (the &#8220;</font><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Press Release</font><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">&#8221;).&#160; Substantially concurrently with the release of the Press Release or otherwise by the applicable deadline for the filing of the Current Report on Form 8-K contemplated by this sentence, the
          Company shall file a Current Report on Form 8-K, which shall be in form and substance reasonably acceptable to the Company and the Elliott Parties (for the avoidance of doubt, nothing herein shall not prohibit the Company from complying with its
          obligation to file such Current Report by the deadline therefor).&#160; The Company shall provide the Elliott Parties and their Representatives with a copy of such Form 8-K prior to its filing with the SEC and shall consider any timely comments of the
          Elliott Parties and their Representatives.&#160; Neither of the Company or any of its Affiliates nor the Elliott Parties or any of their Affiliates shall make any public statement regarding the subject matter of this Agreement, this Agreement or the
          matters set forth in the Press Release prior to the issuance of the Press Release without the prior written consent of the other party.</font></font></div>
    <div style="margin-bottom: 12pt; text-indent: 36pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">4.</font><font style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt">&#160;</font><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Confidentiality; Insider Trading Restrictions</u>.&#160; The Company agrees that the Investor Designee
          may provide confidential information of the Company to the Elliott Parties and their Affiliates for the purpose of assisting the Investor Designee in his or her role as a director of the Company and related compliance matters for the Company and
          the Elliott Group subject to, and solely in accordance with the terms of, a customary confidentiality agreement which the Elliott Parties agree to execute and deliver to the Company simultaneously with the Elliott Parties&#8217; execution and delivery
          of this Agreement (the &#8220;</font><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Confidentiality Agreement</font><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">&#8221;).&#160; The
          Elliott Parties acknowledge that they and their Affiliates are aware that United States securities laws may restrict any person who has material, nonpublic information about a company from purchasing or selling any securities of such company
          while in possession of such information.</font></font></div>
    <div style="margin-bottom: 12pt; text-indent: 36pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">5.</font><font style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt">&#160;</font><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><u>Withdrawal of Nomination Notice</u></font><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">.</font><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">&#160; The Elliott Parties agree that upon appointment of the New Directors to the Board, the nomination notice dated
          August 4, 2022 and delivered to the Company shall be deemed withdrawn and null and void and that the Company need not take any further actions with respect to such notice.</font></font></div>
    <div style="margin-bottom: 12pt; text-indent: 36pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">6.</font><font style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt">&#160;</font><font style="font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><u>Representations and Warranties of the Company</u>.&#160; The Company represents and warrants to the Elliott Parties as follows:&#160; (a) the Company has the power and authority to
        execute, deliver and carry out the terms and provisions of this Agreement and to consummate the transactions contemplated by this Agreement; (b) this Agreement has been duly and validly authorized, executed, and delivered by the Company,
        constitutes a valid and binding obligation and agreement of the Company and is enforceable against the Company in accordance with its terms; and (c) the execution, delivery and performance of this Agreement by the Company does not and will not (i)
        violate or conflict with any law, rule, regulation, order, judgment or decree applicable to the Company, or (ii) result in any breach or violation of or constitute a default (or an event which with notice or lapse of time or both could constitute a
        breach, violation or default) under or pursuant to, or result in the loss of a material benefit under, or give any right of termination, amendment, acceleration or cancellation of, any organizational document, agreement, contract, commitment,
        understanding or arrangement to which the Company is a party or by which it is bound.</font></div>
    <div style="margin-bottom: 12pt; text-indent: 36pt;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 12pt;"> <br>
      </font></div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman', Times, serif; font-size: 11pt; font-weight: normal; font-style: normal;">8</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="margin-bottom: 12pt; text-indent: 36pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">7.</font><font style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt">&#160;</font><font style="font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><u>Representations and Warranties of the Elliott Parties</u>.&#160; Each Elliott Party represents and warrants to the Company as follows:&#160; (a) such Elliott Party has the power and
        authority to execute, deliver and carry out the terms and provisions of this Agreement and to consummate the transactions contemplated by this Agreement; (b) this Agreement has been duly and validly authorized, executed, and delivered by such
        Elliott Party, constitutes a valid and binding obligation and agreement of such Elliott Party and is enforceable against such Elliott Party in accordance with its terms; and (c) the execution, delivery and performance of this Agreement by such
        Elliott Party does not and will not (i) violate or conflict with any law, rule, regulation, order, judgment or decree applicable to such Elliott Party, or (ii) result in any breach or violation of or constitute a default (or an event which with
        notice or lapse of time or both could constitute a breach, violation or default) under or pursuant to, or result in the loss of a material benefit under, or give any right of termination, amendment, acceleration or cancellation of, any
        organizational document, agreement, contract, commitment, understanding or arrangement to which such Elliott Party is a party or by which it is bound.</font></div>
    <div style="margin-bottom: 12pt; text-indent: 36pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">8.</font><font style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt">&#160;</font><font style="font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><u>Definitions</u>.&#160; For purposes of this Agreement:</font></div>
    <div style="margin-bottom: 12pt; text-indent: 36pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">(a)</font><font style="display: inline-block; text-indent: 0px; font-size: 1px; width: 28.8pt">&#160;</font><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">the term </font>&#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Affiliate</font>&#8221; has the meaning set forth in Rule&#160;12b-2 promulgated by the SEC under the Securities Exchange Act of 1934, as amended (the &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Exchange Act</font>&#8221;); provided, that none of the Company or its Affiliates or Representatives, on the one hand, and the Elliott Parties and their Affiliates or Representatives, on the other hand, shall be deemed to be
        &#8220;Affiliates&#8221; with respect to the other for purposes of this Agreement; provided, further, that &#8220;Affiliates&#8221; of a person shall not include any entity, solely by reason of the fact that one or more of such person&#8217;s employees or principals serves as a
        member of its board of directors or similar governing body, unless such person otherwise controls such entity (as the term &#8220;control&#8221; is defined in Rule 12b-2 promulgated by the SEC under the Exchange Act); provided, further, that with respect to
        the Elliott Parties, &#8220;Affiliates&#8221; shall not include any portfolio operating company (as such term is understood in the private equity industry) of any of the Elliott Parties or their Affiliates;</font></div>
    <div style="margin-bottom: 12pt; text-indent: 36pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">(b)</font><font style="display: inline-block; text-indent: 0px; font-size: 1px; width: 28.8pt">&#160;</font><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">the terms &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">beneficial owner</font>&#8221; and &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">beneficially own</font>&#8221; have the same meanings as set forth in Rule 13d-3 promulgated by the SEC under the Exchange Act except that a person will also be deemed to be the
        beneficial owner of all shares of the Company&#8217;s capital stock which such person has the right to acquire (whether such right is exercisable immediately or only after the passage of time) pursuant to the exercise of any rights in connection with any
        securities or any agreement, arrangement or understanding (whether or not in writing), regardless of when such rights may be exercised and whether they are conditional, and all shares of the Company&#8217;s capital stock which such person or any of such
        person&#8217;s Affiliates has or shares the right to vote or dispose;</font></div>
    <div style="margin-bottom: 12pt; text-indent: 36pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">(c)</font><font style="display: inline-block; text-indent: 0px; font-size: 1px; width: 28.8pt">&#160;</font><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">the term &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Expiration Time</font>&#8221; means 11:59 pm., Eastern Time, on the date that
        is five days following the date on which Mr. Barg or any Successor Investor Designee ceases to serve on, or resigns from, the Board;</font></div>
    <div style="margin-bottom: 12pt; text-indent: 36pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">(d)</font><font style="display: inline-block; text-indent: 0px; font-size: 1px; width: 28.8pt">&#160;</font><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">the term &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Independent</font>&#8221; means that such person qualifies as independent of
        the Company under all applicable listing standards, applicable rules of the SEC and publicly disclosed standards used by the Board in determining the independence of the Company&#8217;s directors;</font></div>
    <div style="margin-bottom: 12pt; text-indent: 36pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"> <br>
      </font></div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman', Times, serif; font-size: 11pt; font-weight: normal; font-style: normal;">9</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="margin-bottom: 12pt; text-indent: 36pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">(e)</font><font style="display: inline-block; text-indent: 0px; font-size: 1px; width: 28.8pt">&#160;</font><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">the terms &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">person</font>&#8221; or &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">persons</font>&#8221; mean any individual, corporation (including not-for-profit), general or limited partnership, limited liability or unlimited liability company, joint venture, estate, trust,
        association, organization or other entity of any kind or nature;</font></div>
    <div style="margin-bottom: 12pt; text-indent: 36pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">(f)</font><font style="display: inline-block; text-indent: 0px; font-size: 1px; width: 28.8pt">&#160;</font><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">the term &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Qualified Director</font>&#8221; shall mean an individual who (i) qualifies
        as Independent, (ii) is not an employee, officer, director, general partner, manager or other agent of an Elliott Party or of any Affiliate of an Elliott Party, (iii) is not a limited partner, member or other investor (unless such investment has
        been disclosed to the Company) in any Elliott Party or any Affiliate or Associate of an Elliott Party, (iv) does not have any agreement, arrangement or understanding, written or oral, with any Elliott Party or any Affiliate or Associate of an
        Elliott Party regarding such person&#8217;s service as a director on the Board, and (iv) meets all other qualifications required for service as a director set forth in the Bylaws and the Company&#8217;s Corporate Governance Guidelines (the &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Guidelines</font>&#8221;);</font></div>
    <div style="margin-bottom: 12pt; text-indent: 36pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">(g)</font><font style="display: inline-block; text-indent: 0px; font-size: 1px; width: 28.8pt">&#160;</font><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">the term &#8220;</font><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Representatives</font><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">&#8221; means a party&#8217;s directors, </font>principals, members, general partners, managers, officers, employees, agents, and other
        representatives; and</font></div>
    <div style="margin-bottom: 12pt; text-indent: 36pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">(h)</font><font style="display: inline-block; text-indent: 0px; font-size: 1px; width: 28.8pt">&#160;</font><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">the term &#8220;<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">SEC</font>&#8221; means the U.S. Securities and Exchange Commission.</font></div>
    <div style="margin-bottom: 12pt; text-indent: 36pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"> <br>
      </font></div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman', Times, serif; font-size: 11pt; font-weight: normal; font-style: normal;">10</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="margin-bottom: 12pt; text-indent: 36pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">9.</font><font style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt">&#160;</font><font style="font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><u>Notices</u>.&#160; All notices, consents, requests, instructions, approvals and other communications provided for herein and all legal process in regard to this Agreement will be
        in writing and will be deemed validly given, made or served, if (a) given by facsimile or email, when such facsimile is transmitted to the facsimile number set forth below and sent to the email address set forth below (as applicable), and receipt
        of such facsimile or email (as applicable) is acknowledged, or (b) if given by any other means, when actually received during normal business hours at the address specified in this Section:</font></div>
    <div style="text-align: left; text-indent: 36pt; margin-bottom: 6pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">if to the Company:</div>
    <div style="text-align: left; margin-left: 90pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Cardinal Health, Inc.</div>
    <div style="text-align: left; margin-left: 90pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">7000 Cardinal Place</div>
    <div style="text-align: left; margin-left: 90pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Dublin , Ohio 43017</div>
    <div style="text-align: left; margin-left: 90pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Attention:&#160; Chief Legal Officer</div>
    <div style="text-align: left; margin-left: 90pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Telephone:&#160; 614-747-5000</div>
    <div style="text-align: left; margin-left: 90pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Email:&#160; jessica.mayer@cardinalhealth.com</div>
    <div style="text-align: left; margin-left: 90pt; margin-top: 6pt; margin-bottom: 6pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">with a copy to:</div>
    <div style="text-align: left; margin-left: 90pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Wachtell, Lipton, Rosen &amp; Katz</div>
    <div style="text-align: left; margin-left: 90pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">51 West 52nd Street</div>
    <div style="text-align: left; margin-left: 90pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">New York, New York 10019</div>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="1e3e1cd60ffa486caa52df0f98f7180d" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 90pt;"></td>
          <td style="width: 54pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Attention:</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div><font style="font-size: 12pt;">David A. Katz, Esq.</font><br>
            </div>
            <div><font style="font-size: 12pt;">Sabastian V. Niles, Esq.</font><br>
            </div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" id="z5da082bf0e6e434cb641b535cf19eae7" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 90pt;"><br>
          </td>
          <td style="width: 54pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Email:</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 12pt;">DAKatz@wlrk.com</div>
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 12pt;">SVNiles@wlrk.com </div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="6032c20b307b4c91a26bbd26684b7d4c" class="DSPFListTable">

        <tr>
          <td style="width: 90pt;"></td>
          <td style="width: 54pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Fax:</td>
          <td style="width: auto; vertical-align: top; text-align: left;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">(212) 403-2000</font></td>
        </tr>

    </table>
    <div style="text-align: left; text-indent: 36pt; margin-top: 12pt; margin-bottom: 6pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">if to the Elliott Parties:</div>
    <div style="text-align: left; margin-left: 90pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Elliott Associates, L.P.</div>
    <div style="text-align: left; margin-left: 90pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Elliott International, L.P.</div>
    <div style="text-align: left; margin-left: 90pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">c/o Elliott Investment Management, L.P.</div>
    <div style="text-align: left; margin-left: 90pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">360 S. Rosemary Ave., 18th Floor</div>
    <div style="text-align: left; margin-left: 90pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">West Palm Beach, Florida 33401</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="cb4a8a40036c41c581c675bb48cfdb70" class="DSPFListTable">

        <tr>
          <td style="width: 90pt;"></td>
          <td style="width: 54pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Attention:</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-size: 12pt;"><font style="font-family: 'Times New Roman',Times,serif;">Marc Steinberg</font></div>
            <div><font style="font-size: 12pt;">Scott Grinsell</font><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br>
              </font></div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="053f421c8ee04c95a5c664393f0521a3" class="DSPFListTable">

        <tr>
          <td style="width: 90pt;"></td>
          <td style="width: 54pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Email:</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-size: 12pt;"><font style="font-family: 'Times New Roman',Times,serif;">mSteinberg@elliottmgmt.com</font></div>
            <div><font style="font-size: 12pt;">sGrinsell@elliottmgmt.com</font><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br>
              </font></div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="fe2e1578a6a2427ab4b37aab61293855" class="DSPFListTable">

        <tr>
          <td style="width: 90pt;"></td>
          <td style="width: 54pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Fax:</td>
          <td style="width: auto; vertical-align: top; text-align: left;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">(212) 478-2476</font></td>
        </tr>

    </table>
    <div style="text-align: left; margin-left: 90pt; margin-top: 6pt; margin-bottom: 6pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">with a copy to:</div>
    <div style="text-align: left; margin-left: 90pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Olshan Frome Wolosky LLP</div>
    <div style="text-align: left; margin-left: 90pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">1325 Avenue of the Americas</div>
    <div style="text-align: left; margin-left: 90pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">New York, New York 10019</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="b8c756480bb343429cfbee94ef4ea20a" class="DSPFListTable">

        <tr>
          <td style="width: 90pt;"></td>
          <td style="width: 54pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Attention:</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-size: 12pt;">Steve Wolosky</div>
            <div> <font style="font-size: 12pt;">Andrew Freedman</font></div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="a1fae2d63b7d4a4096bea465fa69cb5f" class="DSPFListTable">

        <tr>
          <td style="width: 90pt;"></td>
          <td style="width: 54pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Email:</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">swolosky@olshanlaw.com</font></div>
            <div>
              <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 12pt;">afreedman@olshanlaw.com</div>
              <font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"> </font></div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="7dc28d657dd74ccab9cde57be642d564" class="DSPFListTable">

        <tr>
          <td style="width: 90pt;"></td>
          <td style="width: 54pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Fax:</td>
          <td style="width: auto; vertical-align: top; text-align: left;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">(212) 451-2222</font></td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="margin-bottom: 12pt; text-indent: 36pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"> <br>
      </font></div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman', Times, serif; font-size: 11pt; font-weight: normal; font-style: normal;">11</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="margin-bottom: 12pt; text-indent: 36pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">10.</font><font style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt">&#160;</font><font style="font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><u>Expenses</u>.&#160; All fees, costs and expenses incurred in connection with this Agreement and all matters related to this Agreement will be paid by the party incurring such
        fees, costs or expenses.</font></div>
    <div style="margin-bottom: 12pt; text-indent: 36pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">11.</font><font style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt">&#160;</font><font style="font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><u>Specific Performance; Remedies; Venue</u>.</font></div>
    <div style="margin-bottom: 12pt; text-indent: 36pt;"><font style="font-size: 12pt; font-family: 'Times New Roman',Times,serif;">(a)</font><font style="display: inline-block; text-indent: 0px; font-size: 1px; width: 28.8pt;"> </font><font style="font-size: 12pt; font-family: 'Times New Roman',Times,serif;">The Company and the Elliott Parties acknowledge and agree that irreparable injury to the other party hereto would occur in the event any of the provisions of this Agreement were
        not performed in accordance with their specific terms or were otherwise breached and that such injury would not be adequately compensable by the remedies available at law (including the payment of money damages).&#160; It is accordingly agreed that the
        Company and the Elliott Parties will be entitled to injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms and provisions of this Agreement, in addition to any other remedy to which they are entitled
        at law or in equity.&#160; FURTHERMORE, THE COMPANY AND EACH ELLIOTT PARTY AGREES (1) THE NON-BREACHING PARTY WILL BE ENTITLED TO INJUNCTIVE AND OTHER EQUITABLE RELIEF, WITHOUT PROOF OF ACTUAL DAMAGES; (2) THE BREACHING PARTY WILL NOT PLEAD IN DEFENSE
        THERETO THAT THERE WOULD BE AN ADEQUATE REMEDY AT LAW; AND (3) THE BREACHING PARTY AGREES TO WAIVE ANY BONDING REQUIREMENT UNDER ANY APPLICABLE LAW, IN THE CASE ANY OTHER PARTY SEEKS TO ENFORCE THE TERMS BY WAY OF EQUITABLE RELIEF.&#160; THIS AGREEMENT
        WILL BE GOVERNED IN ALL RESPECTS, INCLUDING VALIDITY, INTERPRETATION AND EFFECT, BY THE LAWS OF THE STATE OF OHIO WITHOUT GIVING EFFECT TO THE CHOICE OF LAW PRINCIPLES OF SUCH STATE.</font></div>
    <div style="margin-bottom: 12pt; text-indent: 36pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">(b)</font><font style="display: inline-block; text-indent: 0px; font-size: 1px; width: 28.8pt">&#160;</font><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">The Company and each Elliott Party (a) irrevocably and unconditionally submits to the personal jurisdiction of the Ohio State Court (or, only if the Ohio State Court declines to
        accept jurisdiction over a particular matter, the federal or other state courts located in Columbus, Ohio), (b) agrees that it will not attempt to deny or defeat such personal jurisdiction by motion or other request for leave from any such courts,
        (c) agrees that any actions or proceedings arising in connection with this Agreement or the transactions contemplated by this Agreement shall be brought, tried and determined only in such courts, (d) waives any claim of improper venue or any claim
        that those courts are an inconvenient forum and (e) agrees that it will not bring any action relating to this Agreement or the transactions contemplated hereunder in any court other than the aforesaid courts.&#160; The parties to this Agreement agree
        that mailing of process or other papers in connection with any such action or proceeding in the manner provided in Section 8 or in such other manner as may be permitted by applicable law as sufficient service of process, shall be valid and
        sufficient service thereof.</font></div>
    <div style="margin-bottom: 12pt; text-indent: 36pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">12.</font><font style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt">&#160;</font><font style="font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><u>Severability</u>.&#160; If at any time subsequent to the date hereof, any provision of this Agreement is held by any court of competent jurisdiction to be illegal, void or
        unenforceable, such provision will be of no force and effect, but the illegality or unenforceability of such provision will have no effect upon the legality or enforceability of any other provision of this Agreement.</font></div>
    <div style="margin-bottom: 12pt; text-indent: 36pt;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 12pt;"> <br>
      </font></div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman', Times, serif; font-size: 11pt; font-weight: normal; font-style: normal;">12</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="margin-bottom: 12pt; text-indent: 36pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">13.</font><font style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt">&#160;</font><font style="font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><u>Termination</u>.&#160; This Agreement will terminate on the expiry of the Cooperation Period.&#160; Upon such termination, this Agreement shall have no further force and effect.&#160;
        Notwithstanding the foregoing, Sections 8, 9, 10, 11, 12, 13, 15 (solely with respect to provisions that survive termination of this Agreement), 16, 17, 18 and 19 hereof shall survive termination of this Agreement, and no termination of this
        Agreement shall relieve any party of liability for any breach of this Agreement arising prior to such termination.</font></div>
    <div style="margin-bottom: 12pt; text-indent: 36pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">14.</font><font style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt">&#160;</font><font style="font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><u>Counterparts</u>.&#160; This Agreement may be executed in one or more counterparts and by scanned computer image (such as .pdf), each of which will be deemed to be an original
        copy of this Agreement.</font></div>
    <div style="margin-bottom: 12pt; text-indent: 36pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">15.</font><font style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt">&#160;</font><font style="font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><u>Affiliates</u>.&#160; Each of the Elliott Parties agrees that it will cause its Affiliates, including Elliott Management Corporation, and their respective employees and other
        Representatives, to comply with the terms of this Agreement.</font></div>
    <div style="margin-bottom: 12pt; text-indent: 36pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">16.</font><font style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt">&#160;</font><font style="font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><u>No Third-Party Beneficiaries</u>.&#160; This Agreement is solely for the benefit of the Company and the Elliott Parties and is not enforceable by any other persons.&#160; No party to
        this Agreement may assign its rights or delegate its obligations under this Agreement, whether by operation of law or otherwise, without the prior written consent of the other parties, and any assignment in contravention hereof will be null and
        void.</font></div>
    <div style="margin-bottom: 12pt; text-indent: 36pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">17.</font><font style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt">&#160;</font><font style="font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><u>No Waiver</u>.&#160; No failure or delay by any party in exercising any right or remedy hereunder will operate as a waiver thereof, nor will any single or partial waiver thereof
        preclude any other or further exercise thereof or the exercise of any other right or remedy hereunder.</font></div>
    <div style="margin-bottom: 12pt; text-indent: 36pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">18.</font><font style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt">&#160;</font><font style="font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><u>Entire Understanding; Amendment</u>.&#160; This Agreement and the Confidentiality Agreement contain the entire understanding of the parties with respect to the subject matter
        hereof and supersedes any and all prior and contemporaneous agreements, memoranda, arrangements and understandings, both written and oral, between the parties, or any of them, with respect to the subject matter of this Agreement.&#160; This Agreement
        may be amended only by an agreement in writing executed by the Company and the Elliott Parties.</font></div>
    <div style="margin-bottom: 12pt; text-indent: 36pt;"><font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">19.</font><font style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt">&#160;</font><font style="font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><u>Interpretation and Construction</u>.&#160; The Company and each Elliott Party acknowledges that it has been represented by counsel of its choice throughout all negotiations that
        have preceded the execution of this Agreement, and that it has executed the same with the advice of said counsel.&#160; Each party and its counsel cooperated and participated in the drafting and preparation of this Agreement and the documents referred
        to herein, and any and all drafts relating thereto exchanged among the parties will be deemed the work product of all of the parties and may not be construed against any party by reason of its drafting or preparation.&#160; Accordingly, any rule of law
        or any legal decision that would require interpretation of any ambiguities in this Agreement against any party that drafted or prepared it is of no application and is hereby expressly waived by the Company and each Elliott Party, and any
        controversy over interpretations of this Agreement will be decided without regard to events of drafting or preparation.&#160; Whenever the words &#8220;include,&#8221; &#8220;includes&#8221; or &#8220;including&#8221; are used in this Agreement, they shall be deemed to be followed by the
        words &#8220;without limitation.&#8221;</font></div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">[<font style="font-size: 12pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Signature page follows</font>]</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman', Times, serif; font-size: 11pt; font-weight: normal; font-style: normal;">12</font></div>
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: left; text-indent: 36pt; margin-bottom: 14pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">IN WITNESS WHEREOF, this Agreement has been duly executed and delivered by the duly authorized signatories of the
      parties as of the date of this Agreement.</div>
    <div style="text-align: center; margin-bottom: 14pt; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold;"><u>ELLIOTT PARTIES</u></div>
    <table cellspacing="0" cellpadding="0" id="z0fe60d4ec55d43e4a7caabc7bce8c2c1" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 44.17%; vertical-align: top;">&#160;</td>
          <td style="width: 55.83%; vertical-align: top;" colspan="3">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-weight: bold;">ELLIOTT ASSOCIATES, L.P.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 44.17%; vertical-align: top;">&#160;</td>
          <td style="width: 55.83%; vertical-align: top;" colspan="3">&#160;</td>
        </tr>
        <tr>
          <td style="width: 44.17%; vertical-align: top;">&#160;</td>
          <td style="width: 6.58%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">By:</div>
          </td>
          <td style="width: 49.25%; vertical-align: top;" colspan="2">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Elliott Investment Management L.P., as attorney-in-fact</div>
          </td>
        </tr>
        <tr>
          <td style="width: 44.17%; vertical-align: top;">&#160;</td>
          <td style="width: 6.58%; vertical-align: top;">&#160;</td>
          <td style="width: 49.25%; vertical-align: top;" colspan="2">&#160;</td>
        </tr>
        <tr>
          <td style="width: 44.17%; vertical-align: top;">&#160;</td>
          <td style="width: 6.58%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">By:</div>
          </td>
          <td style="width: 49.25%; vertical-align: top; border-bottom: 2px solid #000000;" colspan="2"><font style="font-size: 12pt;">&#160;/s/ Elliot Greenberg</font><br>
          </td>
        </tr>
        <tr>
          <td style="width: 44.17%; vertical-align: top;">&#160;</td>
          <td style="width: 6.58%; vertical-align: top;">&#160;</td>
          <td style="width: 9.4%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Name:</div>
          </td>
          <td style="width: 39.85%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Elliot Greenberg</div>
          </td>
        </tr>
        <tr>
          <td style="width: 44.17%; vertical-align: top;">&#160;</td>
          <td style="width: 6.58%; vertical-align: top;">&#160;</td>
          <td style="width: 9.4%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Title:</div>
          </td>
          <td style="width: 39.85%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Vice President</div>
          </td>
        </tr>

    </table>
    <div style="margin-bottom: 12pt;"><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="zb44a39f3372b4ad2893f6cb8d006c510" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 44.17%; vertical-align: top;">&#160;</td>
          <td style="width: 55.83%; vertical-align: top;" colspan="3">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-weight: bold;">ELLIOTT INTERNATIONAL, L.P.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 44.17%; vertical-align: top;">&#160;</td>
          <td style="width: 55.83%; vertical-align: top;" colspan="3">&#160;</td>
        </tr>
        <tr>
          <td style="width: 44.17%; vertical-align: top;">&#160;</td>
          <td style="width: 6.58%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">By:</div>
          </td>
          <td style="width: 49.25%; vertical-align: top;" colspan="2">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Elliott Investment Management L.P., as attorney-in-fact</div>
          </td>
        </tr>
        <tr>
          <td style="width: 44.17%; vertical-align: top;">&#160;</td>
          <td style="width: 6.58%; vertical-align: top;">&#160;</td>
          <td style="width: 49.25%; vertical-align: top;" colspan="2">&#160;</td>
        </tr>
        <tr>
          <td style="width: 44.17%; vertical-align: top;">&#160;</td>
          <td style="width: 6.58%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">By:</div>
          </td>
          <td style="width: 49.25%; vertical-align: top; border-bottom: 2px solid #000000;" colspan="2"><font style="font-size: 12pt;">&#160;/s/ Elliot Greenberg</font><br>
          </td>
        </tr>
        <tr>
          <td style="width: 44.17%; vertical-align: top;">&#160;</td>
          <td style="width: 6.58%; vertical-align: top;">&#160;</td>
          <td style="width: 9.4%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Name:</div>
          </td>
          <td style="width: 39.85%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Elliot Greenberg</div>
          </td>
        </tr>
        <tr>
          <td style="width: 44.17%; vertical-align: top;">&#160;</td>
          <td style="width: 6.58%; vertical-align: top;">&#160;</td>
          <td style="width: 9.4%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Title:</div>
          </td>
          <td style="width: 39.85%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Vice President</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div><br>
    </div>
    <div style="text-align: center; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif; font-size: 12pt;">*&#160;&#160;*&#160;&#160;*&#160;&#160;*</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman', Times, serif; font-size: 11pt; font-weight: normal; font-style: normal;">13</font></div>
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: center; margin-bottom: 14pt; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold;"><u>THE COMPANY</u></div>
    <div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 44.15%; vertical-align: top;">&#160;</td>
            <td style="width: 55.85%; vertical-align: top;" colspan="2">
              <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-weight: bold;">Cardinal Health, Inc.<br>
              </div>
            </td>
          </tr>
          <tr>
            <td style="width: 44.15%; vertical-align: top;">&#160;</td>
            <td style="width: 55.85%; vertical-align: top;" colspan="2">&#160;</td>
          </tr>
          <tr>
            <td style="width: 44.15%; vertical-align: top;">&#160;</td>
            <td style="width: 6.53%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">By:</div>
            </td>
            <td style="width: 49.22%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);"><font style="font-size: 12pt;">&#160;/s/ Jason Hollar</font><br>
            </td>
          </tr>
          <tr>
            <td style="width: 44.15%; vertical-align: top;">&#160;</td>
            <td style="width: 6.53%; vertical-align: top; font-size: 12pt;">Name:</td>
            <td style="width: 9.36%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">
                <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Jason Hollar<br>
                </div>
              </div>
            </td>
          </tr>
          <tr>
            <td style="width: 44.15%; vertical-align: top;">&#160;</td>
            <td style="width: 6.53%; vertical-align: top;"><font style="font-size: 12pt;">Title:</font><br>
            </td>
            <td style="width: 9.36%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Chief Executive Officer<br>
              </div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman', Times, serif; font-size: 11pt; font-weight: normal; font-style: normal;">14</font></div>
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: center; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-weight: bold;"><u>Exhibit A</u></div>
    <div style="text-align: center; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-weight: bold;">Form of Press Release</div>
    <div style="text-align: center; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">Filed separately as Exhibit 99.1 to the Current Report on Form 8-K</div>
    <div style="text-align: center; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"> <br>
    </div>
    <div><br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman', Times, serif; font-size: 11pt; font-weight: normal; font-style: normal;">15</font></div>
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: center; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-weight: bold;"><u>Exhibit B</u></div>
    <div style="text-align: center; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-weight: bold;">
      <div style="text-align: center; margin-bottom: 8pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-weight: bold;"><u>FORM OF BUSINESS REVIEW COMMITTEE CHARTER</u></div>
      <div style="text-align: justify; margin-bottom: 8pt; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: normal;">1. Members. The Board of Directors (the &#8220;Board&#8221;) of Cardinal Health, Inc. (the &#8220;Company&#8221;) will appoint a Business
        Review Committee (the &#8220;Committee&#8221;) of three members, consisting of the Chief Executive Officer as the chairperson of the Committee, Mr. Steven Barg and one other independent director, who shall be Akhil Johri.&#160; For purposes of this Charter, an
        &#8220;independent&#8221; director is a director who meets the independence requirements of the New York Stock Exchange, as determined by the Board using the standards set forth in the Company&#8217;s Corporate Governance Guidelines.&#160; Vacancies on the Committee
        shall be filled by the Board and in accordance with the terms of that certain Cooperation Agreement, dated as of September 5, 2022 (the &#8220;Cooperation Agreement&#8221;), by and among Elliott Investment Management L.P., Elliott Associates, L.P., and Elliott
        International, L.P., (collectively, &#8220;Elliott&#8221;) and the Company, provided that any new member of the Committee (other than the Company&#8217;s Chief Executive Officer) must be an independent director.</div>
      <div style="text-align: justify; margin-bottom: 8pt; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: normal;">2. Purpose, Duties and Responsibilities. The purpose of the Committee is to review the operations and business of
        the Company as well as the Company&#8217;s capital allocation policy in order to maximize long-term value of the Company.&#160; The initial focus of the Committee will be a review of the Company&#8217;s overall business strategy and its portfolio of businesses and
        assets.&#160; In furtherance of this purpose, the Committee shall review, evaluate and make recommendations to the Board regarding the following matters, including (to the extent applicable) the timing for and supporting the Board&#8217;s oversight as to the
        implementation of:</div>
      <div style="text-align: justify; margin-left: 40.5pt; margin-bottom: 8pt; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: normal;">(a) the Company&#8217;s portfolio of businesses and assets (including identifying and evaluating
        potential opportunities and options that may be available, relative to the current configuration of such businesses, as well as potential strategic opportunities with respect to such businesses);</div>
      <div style="text-align: justify; margin-left: 40.5pt; margin-bottom: 8pt; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: normal;">(b) the strategy, operations and business of the Company (including identifying opportunities
        to enhance the competitive positioning and business and financial profile of the Company&#8217;s assets and businesses, both individually and as a whole, taking into account the portfolio review and the results of such review);</div>
      <div style="text-align: justify; margin-left: 40.5pt; margin-bottom: 8pt; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: normal;">(c) long-term planning, priorities, corporate strategies and oversight;</div>
      <div style="text-align: justify; margin-left: 40.5pt; margin-bottom: 8pt; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: normal;">(d) capital allocation priorities, including as to capital return policies, multi-year
        financial plan(s) and any additional capital return opportunities resulting from the portfolio review; and</div>
      <div style="text-align: justify; margin-left: 40.5pt; margin-bottom: 8pt; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: normal;">(e) any other related matters as may be determined by the Board from time to time.</div>
      <div style="text-align: justify; margin-bottom: 8pt; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: normal;">The Committee will make recommendations to the Board with respect to the results of such review as promptly as
        practicable following the completion of the Committee&#8217;s work.&#160; For the avoidance of doubt, any Committee member is permitted to privately share his or her views and recommendations to the Board regarding the results of the Committee&#8217;s review and
        any other matters that may be considered in furtherance of the Committee&#8217;s purposes.</div>
      <div style="text-align: justify; margin-bottom: 8pt; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: normal;">The results of such review shall be reported to the Company&#8217;s shareholders at an Investors Day to take place no
        later than June 30, 2023 (the &#8220;Investor Day&#8221;).&#160; The Committee shall consult with management and the Board with respect to the Company&#8217;s communications to be issued in connection with the Investor Day and the timing of such Investor Day, with the
        goal of having such Investor Day occur at an appropriate time following the Board reaching its determinations regarding the Committee&#8217;s review (it being understood for the avoidance of doubt that the Board and management have the discretion not to
        wait until Investor Day to execute on any initiatives or announce the completion of any initiatives).&#160; The Committee&#8217;s recommendations to the Board shall be confidential, non-binding and advisory in nature.&#160; For the avoidance of doubt, the
        Committee&#8217;s deliberations, materials reviewed, conclusions, communications, findings, and recommendations shall be private and kept strictly confidential, including in accordance with the Board&#8217;s policies.&#160; Members of the Committee shall
        communicate with Company management and employees in accordance with the Board&#8217;s ordinary course communication practices for other committees and only to the extent appropriate with their duties to fulfill the Committee&#8217;s purposes.&#160; Management of
        the Company shall provide assistance to the Committee in connection with the Committee&#8217;s purpose.</div>
      <div style="text-align: justify; margin-bottom: 8pt; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: normal;">3. Outside Advisors. In furtherance of the Committee&#8217;s purpose, the Committee has the authority to retain such
        outside counsel, experts, consultants, and other advisors as it determines appropriate, which may include outside counsel, experts, and other advisors already retained by the Company.&#160; The Company shall be responsible for paying the reasonable fees
        and expenses of such advisors.</div>
      <div style="text-align: justify; margin-bottom: 8pt; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: normal;">4. Meetings; Reporting to Board. The majority of the members of the Committee constitutes a quorum. The Committee
        may act by a majority vote of the members present at a meeting of the Committee at which a quorum exists or by a writing or writings signed by all of its members without a meeting. Meetings of the Committee generally will be held periodically as
        circumstances dictate, with the Committee&#8217;s initial meeting to be held no later than September 29, 2022, and otherwise at such times and places, as the Committee determines appropriate. Such meetings may be held through any communications equipment
        if all persons participating can hear each other. The chairperson shall chair all regular sessions on the Committee and may call, and upon the request of any other member of the Committee shall call, and convene meetings of the Committee. The
        chairperson shall be responsible for setting the agendas for Committee meetings. The Committee shall report regularly to the full Board with respect to its meetings and concerning significant developments in the course of the review specified in
        Section 2 above, which reports may occur at the regularly scheduled meetings of the Board (or more frequently as requested by the Chair of the Board or as determined by the chairperson of the Committee).&#160; The Committee shall keep minutes of its
        meetings and shall periodically review its performance.</div>
      <div style="text-align: justify; margin-bottom: 8pt; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: normal;">5. Term.&#160; The Committee will disband following the Investor Day, unless the Board should otherwise determine to
        extend the term of the Committee.</div>
    </div>
    <div style="text-align: center; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-weight: bold;"> <font style="font-weight: normal;"><br>
      </font></div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman', Times, serif; font-size: 11pt; font-weight: normal; font-style: normal;">16</font></div>
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>exhibit99-1pressrelease.htm
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Wachtell, Lipton, Rosen & Katz
         Document created using Broadridge PROfile 22.7.2.5063
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <!--PROfilePageNumberReset%Num%1%%%-->
  <div>
    <div><br>
    </div>
    <div style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: bold;"> <font style="font-size: 12pt;"><u><font style="font-weight: bold;">EXHIBIT 99.1</font></u></font> </div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Cardinal Health Announces Governance Enhancements and Shareholder Value Creation Initiatives</div>
    <div><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Adds Four New Independent Directors to the Board</div>
    <div><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Forms New Business Review Committee to Evaluate Portfolio and Operations</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">DUBLIN, Ohio, Sept. 6, 2022 &#8211;</font> Cardinal Health (NYSE:
      CAH) today announced initiatives aimed at positioning the Company for long-term success, building on Cardinal Health&#8217;s previously announced growth plans. These initiatives have benefited from input received from Elliott Investment Management L.P.
      (&#8220;Elliott&#8221;).&#160; In connection with these initiatives, Elliott has also entered into a cooperation agreement with Cardinal Health, and Elliott&#8217;s Steven Barg will join the Company&#8217;s Board of Directors.</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">As part of Cardinal Health&#8217;s ongoing commitment to Board refreshment and the initiatives announced today, the Governance and Sustainability Committee of the
      Board has recommended and the Board has approved the appointment of four new independent directors: Steven Barg, Michelle Brennan, Sujatha Chandrasekaran and Christine Mundkur. With these immediate appointments, Cardinal Health&#8217;s Board will be made
      up of 15 Directors, 14 of whom are independent under the Company&#8217;s director independence standards. Two existing Directors &#8211; Dean Scarborough and John Weiland &#8211; have announced their intentions to conclude their Board service at the end of their
      previously elected terms this fall and will not stand for re-election at Cardinal Health&#8217;s 2022 Annual Meeting, resulting in a 13-member Board.&#160; Following the Annual Meeting, Cardinal Health&#8217;s Board will consist of 54% women and 23% racially or
      ethnically diverse individuals.</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Cardinal Health&#8217;s Board has also formed a new Board committee, the Business Review Committee, to support a comprehensive review of the Company&#8217;s strategy,
      portfolio, capital-allocation framework, and operations with the goal of maximizing Cardinal Health&#8217;s potential for the benefit of all stakeholders. The Business Review Committee will be chaired by Chief Executive Officer Jason Hollar; Mr. Barg and
      Akhil Johri will also serve on the Committee. The Committee, with the assistance of the Company&#8217;s legal and financial advisors, will make recommendations to the full Board. The Company expects to conduct an investor day in the first half of calendar
      2023 to share the Board&#8217;s conclusions and to provide additional guidance.</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8220;We&#8217;d like to thank Dean and John for their service to the Board. We&#8217;re grateful for their leadership and contributions and wish them both the very best,&#8221;
      said Gregory Kenny, Independent Chairman of the Board of Cardinal Health. &#8220;We&#8217;re pleased to welcome Steven, Michelle, Sujatha and Christine to the Board and believe the Company and our many stakeholders will benefit from their mix of experience,
      skills and leadership. We are also pleased with Elliott&#8217;s confidence in, and commitment to, the go-forward long-term potential of Cardinal Health. Our Board looks forward to receiving the recommendations of the Business Review Committee and updating
      the market in due course, as Jason and his leadership team chart a path to deliver upon our mission for our customers and employees and drive value creation for our shareholders.&#8221;</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8220;Cardinal Health&#8217;s leadership team is focused on creating value for all our stakeholders, and the newly initiated Business Review Committee, as well as the
      new expertise and experience being added to our Board, are critical steps in this process,&#8221; said Mr. Hollar, Cardinal Health&#8217;s Chief Executive Officer. &#8220;I look forward to working with the Board, including our four new directors, to optimize our
      strategy, structure, and operations as we position Cardinal Health for long-term success.&#8221;</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Elliott Senior Portfolio Manager Marc Steinberg said, &#8220;Our discussions with Jason and the Board have been positive and productive, and we are pleased to have
      worked collaboratively to reach this agreement. Cardinal Health plays a mission-critical, market-leading role in the global healthcare system, and we have been encouraged by the Company&#8217;s openness to taking actions necessary to ensuring that Cardinal
      Health realizes its full potential. We are confident that the initiatives announced today will drive meaningful shareholder value creation, and we look forward to continuing our collaboration with the Company.&#8221;</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The cooperation agreement that the Company has entered into with Elliott contains customary standstill, voting, confidentiality and other provisions.</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Goldman Sachs &amp; Co. LLC is serving as financial advisor to Cardinal Health, and Wachtell, Lipton, Rosen &amp; Katz is serving as legal counsel, both of
      whom will also support the Business Review Committee and Board&#8217;s reviews.</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman', Times, serif; font-size: 11pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">1</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><u>New Director Biographies</u></div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Steven Barg</font> is Global Head of Engagement at Elliott
      Management Corporation. Prior to joining Elliott in February of 2020, Mr. Barg spent 30 years in investment banking, most recently as a Participating Managing Director at Goldman Sachs. During his time at Goldman Sachs, Mr. Barg established and led
      what became the firm&#8217;s Global Activism and Shareholder Advisory practice; founded and led the M&amp;A Capital Markets practice; and served as Co-Head of Asian Equity Capital Markets in Hong Kong. In addition, Mr. Barg served on both the Asian and
      Global Equity Commitments Committees and was Global Head of Diversity for the Investment Banking Division. Prior to joining Goldman Sachs, Mr. Barg ran the Asian Equity Capital Markets and later the Integrated Capital Markets business at UBS and
      served as a managing director in Equity Capital Markets at Credit Suisse in New York and London.</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Mr. Barg holds an M.B.A. from the Stanford University Graduate School of Business and a B.A. from Wesleyan University. In addition, Mr. Barg was a Henry Luce
      Scholar in Hong Kong and a Coro Fellow in Public Affairs in New York.</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Michelle Brennan </font>is Chair of Connect Healthcare
      Council for Pioneering Collective and serves on the Board of Coupa Software. Ms. Brennan spent more than 30 years at Johnson &amp; Johnson, a leader in the field of medical devices, pharmaceutical, and consumer packaged goods, where she focused on
      driving growth, optimization and business transformation across diverse businesses and geographies. Most recently, Ms. Brennan served as the Global Value Creation Leader for Johnson &amp; Johnson and as a member of the company&#8217;s Medical Device
      Executive Leadership Team responsible for the division&#8217;s value creation through cost management initiatives. Prior to that, Ms. Brennan held a number of positions at Johnson &amp; Johnson, including Company Group Chair, Medical Devices (EMEA);
      President, Enterprise Standards &amp; Productivity; Worldwide President, Ethicon Energy; as well as a variety of sales and marketing positions for other Johnson &amp; Johnson divisions. Throughout her time at Johnson &amp; Johnson, Ms. Brennan held
      significant board roles for the company, including Chairman of the Board for Medtech Europe Trading Association. She was previously a member of the UK&#8217;s Office of Life Sciences Council and Chairman of the Council&#8217;s Health Technology Partnership
      Committee.</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Ms. Brennan holds a B.S. from the University of Kansas.</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Sujatha Chandrasekaran</font>, also known as Suja, is an
      advisor and independent consultant in the research and technology sectors. She currently serves on the Board of American Eagle Outfitters as well as private companies including Agendia, a molecular diagnostics company, and Blume Global, a digital
      supply chain platform company. Ms. Chandrasekaran has more than 25 years of experience in technology and leadership roles across the healthcare, consumer packaged goods and retail industries. Most recently, Ms. Chandrasekaran was Senior EVP &amp;
      Chief Digital and Information Officer at CommonSpirit Health, one of the largest non-profit health systems in the US. Prior to that, she held a number of senior executive roles at several Fortune 500 multinational companies, including Global Chief
      Information Officer for Kimberly-Clark; SVP, Global Chief Technology and Data Officer for Walmart; as well as a number of C-level roles at The Timberland Company, PepsiCo and Nestl&#233; SA. Ms. Chandrasekaran has a strong track record of delivering
      significant value to customers and organizations by leading global technology, supply chain and digital transformation initiatives. In 2022, Ms. Chandrasekaran was recognized by Modern Healthcare as one of the Top 25 Women Leaders in Healthcare. <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">She was previously a Director of Symphony Technology Group and a Director of Barry Callebaut AG as well as a Member of Advisory Board at Atmio Inc.</font></div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Ms. Chandrasekaran holds an Executive Development Education Certificate from London Business School; a Master of Business Systems/M.B.A. from Monash
        University in Melbourne, Australia; and a B.Eng. from the University of Madras, India.</div>
    <div><br>
    </div>
    <div>
      <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Christine Mundkur </font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">most recently served as Chief Executive Officer and Non-Voting Chairman of the Board of Directors for Impopharma Inc, a developer of complex formulations focused on inhalation pharmaceutical
          products.&#160;Ms. Mundkur currently serves on the Boards of Lupin Limited and MannKind Corporation. While at Impopharma, she led the transition of the company from a successful clinical research organization into a generic pharmaceutical inhalation
          development company. She also held leadership positions as President and Chief Executive Officer for North America for Sandoz, Inc. Earlier, she served as Chief Executive Officer of Barr Laboratories, Inc. Ms. Mundkur started her career at Barr
          as quality and regulatory counsel. In addition, she served as a strategic advisor to clients on generics, 505(b)2, biosimilars and NDA business strategies.</font></div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Ms. Mundkur holds a J.D. from the St. Louis University School of Law and a B.S. from St. Louis University.</div>
      <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> <br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman', Times, serif; font-size: 11pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">2</font></div>
        <div style="page-break-after: always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
    </div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">About Cardinal Health</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><br>
      </font>Cardinal Health is a distributor of pharmaceuticals, a global manufacturer and distributor of medical and laboratory products, and a provider of performance and data solutions for health care facilities. With 50 years in business, operations
      in more than 30 countries and approximately 44,000 employees globally, Cardinal Health is essential to care. Information about Cardinal Health is available at&#160;cardinalhealth.com.</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Contacts</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><br>
      </font>Media:&#160;Erich Timmerman,&#160;erich.timmerman@cardinalhealth.com&#160;and 614.757.8231<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><br>
      </font>Investors:&#160;Kevin Moran,&#160;kevin.moran@cardinalhealth.com&#160;and 614.757.7942</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Cautions concerning forward-looking statements</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">This release contains forward-looking statements addressing expectations, prospects, estimates and other matters that are dependent upon future events or
      developments. These statements may be identified by words such as "expect," "anticipate," "intend," "plan," "believe," "will," "should," "could," "would," "project," "continue," "likely," and similar expressions, and include statements reflecting
      future results or guidance, statements of outlook and various accruals and estimates. These matters are subject to risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied. These risks
      and uncertainties include risks arising from ongoing inflationary pressures and supply chain constraints, including the risk that our plans to mitigate such effects may not be as successful as we anticipate and the possibility that costs to source
      certain personal protective or other equipment, increased costs for transportation, shipping, freight and commodities, reduced price or demand for certain products may result in additional inventory reserves or disruptions and may negatively impact
      our ability to meet our long-term guidance; the possibility that our Medical unit goodwill could be further impaired, the increase in global interest rates or possible unfavorable changes in the U.S. statutory tax rate; competitive pressures in
      Cardinal Health's various lines of business; the performance of our generics program, including the amount or rate of generic deflation and our ability to offset generic deflation and maintain other financial and strategic benefits through our
      generic sourcing venture with CVS Health; ongoing risks associated with the distribution of opioids, including the financial impact associated with the settlements with governmental authorities, the risk that challenges to our plans to take tax
      deductions for opioid-related losses could adversely impact our financial results, risks arising from the Department of Justice investigation which we believe concerns our anti-diversion program and risks associated with the injunctive relief
      requirements under the national settlement, including the risk that we may incur higher costs or operational challenges in the implementation and maintenance of the required changes; risks associated with the manufacture and sourcing of certain
      products, including risks related to our ability and the ability of third-party manufacturers to import or export certain products or component parts and to comply with applicable regulations; risks associated with the competitive labor market and
      our ability to attract and retain employees in key roles; our ability to manage uncertainties associated with the pricing of branded pharmaceuticals; and risks associated with our cost savings initiatives or other business initiatives, such as the
      Medical Improvement Plan, including the possibility that they could fail to achieve the intended results. Cardinal Health is subject to additional risks and uncertainties described in Cardinal Health's Form 10-K, Form 10-Q and Form 8-K reports and
      exhibits to those reports. This release reflects management's views as of September 6, 2022. Except to the extent required by applicable law, Cardinal Health undertakes no obligation to update or revise any forward-looking statement. Forward-looking
      statements are aspirational and not guarantees or promises that goals, targets or projections will be met, and no assurance can be given that any commitment, expectation, initiative or plan in this report can or will be achieved or completed.</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> <br>
    </div>
  </div>
  <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman', Times, serif; font-size: 11pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">3</font></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>cah-20220905.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 22.7.2.5063 Broadridge-->
<xs:schema targetNamespace="http://cardinalhealth.com/20220905" elementFormDefault="qualified" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:cah="http://cardinalhealth.com/20220905" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="cah-20220905_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="cah-20220905_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://cardinalhealth.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000100 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/currency/2022" schemaLocation="https://xbrl.sec.gov/currency/2022/currency-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/exch/2022" schemaLocation="https://xbrl.sec.gov/exch/2022/exch-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/naics/2022" schemaLocation="https://xbrl.sec.gov/naics/2022/naics-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/sic/2022" schemaLocation="https://xbrl.sec.gov/sic/2022/sic-2022.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/stpr/2022" schemaLocation="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" />
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2004/ref" schemaLocation="http://www.xbrl.org/2004/ref-2004-08-10.xsd" />
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xs:import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
  <xs:import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd" />
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>cah-20220905_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 22.7.2.5063 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:label xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CoverAbstract_lbl" xml:lang="en-US" id="dei_CoverAbstract_lbl">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:title="label: CoverAbstract to dei_CoverAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentType_lbl" xml:lang="en-US" id="dei_DocumentType_lbl">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentType" xlink:to="dei_DocumentType_lbl" xlink:title="label: DocumentType to dei_DocumentType_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:label xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_WrittenCommunications_lbl" xml:lang="en-US" id="dei_WrittenCommunications_lbl">Written Communications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:title="label: WrittenCommunications to dei_WrittenCommunications_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:label xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SolicitingMaterial_lbl" xml:lang="en-US" id="dei_SolicitingMaterial_lbl">Soliciting Material</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:title="label: SolicitingMaterial to dei_SolicitingMaterial_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" id="dei_PreCommencementTenderOffer_lbl">Pre-commencement Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:title="label: PreCommencementTenderOffer to dei_PreCommencementTenderOffer_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" id="dei_PreCommencementIssuerTenderOffer_lbl">Pre-commencement Issuer Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:title="label: PreCommencementIssuerTenderOffer to dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:label xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_AmendmentFlag_lbl" xml:lang="en-US" id="dei_AmendmentFlag_lbl">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:title="label: AmendmentFlag to dei_AmendmentFlag_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalYearFocus_lbl">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:title="label: DocumentFiscalYearFocus to dei_DocumentFiscalYearFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalPeriodFocus_lbl">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:title="label: DocumentFiscalPeriodFocus to dei_DocumentFiscalPeriodFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" id="dei_DocumentPeriodEndDate_lbl">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:title="label: DocumentPeriodEndDate to dei_DocumentPeriodEndDate_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:label xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityRegistrantName_lbl" xml:lang="en-US" id="dei_EntityRegistrantName_lbl">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:title="label: EntityRegistrantName to dei_EntityRegistrantName_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" id="dei_EntityCentralIndexKey_lbl">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:title="label: EntityCentralIndexKey to dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityFileNumber_lbl" xml:lang="en-US" id="dei_EntityFileNumber_lbl">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:title="label: EntityFileNumber to dei_EntityFileNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" id="dei_EntityTaxIdentificationNumber_lbl">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:title="label: EntityTaxIdentificationNumber to dei_EntityTaxIdentificationNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" id="dei_EntityIncorporationStateCountryCode_lbl">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:title="label: EntityIncorporationStateCountryCode to dei_EntityIncorporationStateCountryCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:label xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" id="dei_EntityEmergingGrowthCompany_lbl">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:title="label: EntityEmergingGrowthCompany to dei_EntityEmergingGrowthCompany_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine1_lbl">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:title="label: EntityAddressAddressLine1 to dei_EntityAddressAddressLine1_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine2_lbl">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:title="label: EntityAddressAddressLine2 to dei_EntityAddressAddressLine2_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine3_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine3_lbl">Entity Address, Address Line Three</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:title="label: EntityAddressAddressLine3 to dei_EntityAddressAddressLine3_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" id="dei_EntityAddressCityOrTown_lbl">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:title="label: EntityAddressCityOrTown to dei_EntityAddressCityOrTown_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" id="dei_EntityAddressStateOrProvince_lbl">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:title="label: EntityAddressStateOrProvince to dei_EntityAddressStateOrProvince_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCountry_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCountry_lbl" xml:lang="en-US" id="dei_EntityAddressCountry_lbl">Entity Address, Country</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:title="label: EntityAddressCountry to dei_EntityAddressCountry_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" id="dei_EntityAddressPostalZipCode_lbl">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:title="label: EntityAddressPostalZipCode to dei_EntityAddressPostalZipCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:label xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CityAreaCode_lbl" xml:lang="en-US" id="dei_CityAreaCode_lbl">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:title="label: CityAreaCode to dei_CityAreaCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:label xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_LocalPhoneNumber_lbl" xml:lang="en-US" id="dei_LocalPhoneNumber_lbl">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:title="label: LocalPhoneNumber to dei_LocalPhoneNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:label xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_Security12bTitle_lbl" xml:lang="en-US" id="dei_Security12bTitle_lbl">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:title="label: Security12bTitle to dei_Security12bTitle_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:label xlink:type="resource" xlink:label="dei_NoTradingSymbolFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US" id="dei_NoTradingSymbolFlag_lbl">No Trading Symbol Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:title="label: NoTradingSymbolFlag to dei_NoTradingSymbolFlag_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:label xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_TradingSymbol_lbl" xml:lang="en-US" id="dei_TradingSymbol_lbl">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:title="label: TradingSymbol to dei_TradingSymbol_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:label xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SecurityExchangeName_lbl" xml:lang="en-US" id="dei_SecurityExchangeName_lbl">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:title="label: SecurityExchangeName to dei_SecurityExchangeName_lbl" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>cah-20220905_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 22.7.2.5063 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://cardinalhealth.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="cah-20220905.xsd#DocumentAndEntityInformation" />
  <link:presentationLink xlink:type="extended" xlink:role="http://cardinalhealth.com/role/DocumentAndEntityInformation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentType" xlink:title="presentation: CoverAbstract to DocumentType" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="AmendmentFlag" xlink:title="presentation: CoverAbstract to AmendmentFlag" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentPeriodEndDate" xlink:title="presentation: CoverAbstract to DocumentPeriodEndDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalYearFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalYearFocus" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalPeriodFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalPeriodFocus" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityFileNumber" xlink:title="presentation: CoverAbstract to EntityFileNumber" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityRegistrantName" xlink:title="presentation: CoverAbstract to EntityRegistrantName" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityCentralIndexKey" xlink:title="presentation: CoverAbstract to EntityCentralIndexKey" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityIncorporationStateCountryCode" xlink:title="presentation: CoverAbstract to EntityIncorporationStateCountryCode" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityTaxIdentificationNumber" xlink:title="presentation: CoverAbstract to EntityTaxIdentificationNumber" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine1" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine1" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine2" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine2" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine3" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine3" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCityOrTown" xlink:title="presentation: CoverAbstract to EntityAddressCityOrTown" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressStateOrProvince" xlink:title="presentation: CoverAbstract to EntityAddressStateOrProvince" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCountry" xlink:title="presentation: CoverAbstract to EntityAddressCountry" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressPostalZipCode" xlink:title="presentation: CoverAbstract to EntityAddressPostalZipCode" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="CityAreaCode" xlink:title="presentation: CoverAbstract to CityAreaCode" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="LocalPhoneNumber" xlink:title="presentation: CoverAbstract to LocalPhoneNumber" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="NoTradingSymbolFlag" xlink:title="presentation: CoverAbstract to NoTradingSymbolFlag" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityEmergingGrowthCompany" xlink:title="presentation: CoverAbstract to EntityEmergingGrowthCompany" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="WrittenCommunications" xlink:title="presentation: CoverAbstract to WrittenCommunications" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SolicitingMaterial" xlink:title="presentation: CoverAbstract to SolicitingMaterial" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementTenderOffer" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementIssuerTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementIssuerTenderOffer" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="Security12bTitle" xlink:title="presentation: CoverAbstract to Security12bTitle" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="TradingSymbol" xlink:title="presentation: CoverAbstract to TradingSymbol" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SecurityExchangeName" xlink:title="presentation: CoverAbstract to SecurityExchangeName" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139782793873216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Sep. 05, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep.  05,  2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">1-11373<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Cardinal Health, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000721371<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">OH<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">31-0958666<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">7000 Cardinal Place<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Dublin<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">OH<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">43017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">614<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">757-5000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common shares (without par value)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CAH<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>22-9-6cah8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="cah-20220905.xsd" xlink:type="simple"/>
    <context id="c20220905to20220905">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <startDate>2022-09-05</startDate>
            <endDate>2022-09-05</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="c20220905to20220905"
      id="Fact_190409351da945fbbe65eee91acf4ccf">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="c20220905to20220905"
      id="Fact_6a706bd7defc4405b0f6133a87afad33">0000721371</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="c20220905to20220905"
      id="Fact_fd6830dfec8d466d94d6582d40d505b6">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="c20220905to20220905"
      id="Fact_8a316df863124678b5c83739c0585773">2022-09-05</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="c20220905to20220905"
      id="Fact_3df6f15f9bd74631b2d31c4c6ebb6171">Cardinal Health, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="c20220905to20220905"
      id="Fact_c3b1d169ef414924b552b71fe310aa6c">OH</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="c20220905to20220905"
      id="Fact_2b284246a74a425383214deff041088f">1-11373</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="c20220905to20220905"
      id="Fact_b311b2c4ae6c440ba28c85adeebaff6c">31-0958666</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="c20220905to20220905"
      id="Fact_3436f610b82a4d8abdfd0e826a4ea1a3">7000 Cardinal Place</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="c20220905to20220905"
      id="Fact_4d6b55d1e8a041f98e71cc4e7f36a307">Dublin</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="c20220905to20220905"
      id="Fact_9aa7cb6ccba443469b38ecf4c6c9ee85">OH</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="c20220905to20220905"
      id="Fact_e0e5bf1a14194858af05ae9a3c41077d">43017</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="c20220905to20220905"
      id="Fact_4b357bf6dfbe41538e65aece1b403146">614</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="c20220905to20220905"
      id="Fact_db9da761cb6841249ee987c40852f164">757-5000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="c20220905to20220905"
      id="Fact_dc4667a2c441463ba5cba63cacedd55a">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="c20220905to20220905"
      id="Fact_9011cd45df8f4d2b9f38cc3c690471b1">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="c20220905to20220905"
      id="Fact_a486052835e54f8a938d1265b80704e8">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="c20220905to20220905"
      id="Fact_0bb0e6c2250c4c8c8a585c6c8df538b4">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="c20220905to20220905"
      id="Fact_8335989fbb8c44b89d720c1f59ea144d">Common shares (without par value)</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="c20220905to20220905"
      id="Fact_23c697ef21c34b9f8f3b6020f745b3e3">CAH</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="c20220905to20220905"
      id="Fact_134357ea92c44f139950700ff0dcadf9">NYSE</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="c20220905to20220905"
      id="Fact_b58c59e76f0b42e6a1276c685540f93d">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M])H57%U?F)Q%?.Q!X1JNG[DW^? ;'02_(WS=BJ^+J=<)?'K->1,<'G[6^8)
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M#RP/9'I;K?%NXQ/R^AQ@/7UM0K"=XI.([12O-2#QNH%'GL>[C>4!#ZP+V.Q
M_G@>F*FX3YI"5S%NV G&D3S'$)C%^(QF&5*=##[Q_F"G)$WS/(X %F>0IA@"
MIQ%', ;  4/2='@//GL?)=-[*CG_5U/\!%!+ P04    "  K-R95EXJ[',
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M)E4<.&7J/P$  #P"   /    >&PO=V]R:V)O;VLN>&ULC5'+;L) #/R5U7Y
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M%0:P;W(@"2[)E1M27>EYIK=WDWM)J'7N0;#W\!J-'<V/'[?\ 5!+ P04
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MUDX:?^:+X3]>?P%02P$"% ,4    "  K-R95!T%-8H$   "Q    $
M        @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( "LW)E7D
M&MTX[P   "L"   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM
M;%!+ 0(4 Q0    ( "LW)E697)PC$ 8  )PG   3              "  <T!
M  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ *S<F56B79!I$!
MBA   !@              ("!#@@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM
M;%!+ 0(4 Q0    ( "LW)E6?H!OPL0(  .(,   -              "  8@,
M  !X;"]S='EL97,N>&UL4$L! A0#%     @ *S<F59>*NQS     $P(   L
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64$L%!@     )  D /@(  .@3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="22-9-6cah8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000100 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cardinalhealth.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="22-9-6cah8k.htm">22-9-6cah8k.htm</File>
    <File>cah-20220905.xsd</File>
    <File>cah-20220905_lab.xml</File>
    <File>cah-20220905_pre.xml</File>
    <File>exhibit10-1.htm</File>
    <File>exhibit99-1pressrelease.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "22-9-6cah8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "22-9-6cah8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "cah-20220905_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cah-20220905_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "cah-20220905.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2004/ref-2004-08-10.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/currency/2022/currency-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/exch/2022/exch-2022.xsd",
      "https://xbrl.sec.gov/naics/2022/naics-2022.xsd",
      "https://xbrl.sec.gov/sic/2022/sic-2022.xsd",
      "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
     ]
    }
   },
   "elementCount": 29,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 22,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "cah",
   "nsuri": "http://cardinalhealth.com/20220905",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "22-9-6cah8k.htm",
      "contextRef": "c20220905to20220905",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000100 - Document - Document and Entity Information",
     "role": "http://cardinalhealth.com/role/DocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "22-9-6cah8k.htm",
      "contextRef": "c20220905to20220905",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cardinalhealth.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cardinalhealth.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cardinalhealth.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cardinalhealth.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cardinalhealth.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cardinalhealth.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cardinalhealth.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cardinalhealth.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cardinalhealth.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cardinalhealth.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cardinalhealth.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cardinalhealth.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cardinalhealth.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cardinalhealth.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cardinalhealth.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cardinalhealth.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cardinalhealth.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cardinalhealth.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cardinalhealth.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cardinalhealth.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cardinalhealth.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cardinalhealth.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cardinalhealth.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cardinalhealth.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cardinalhealth.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cardinalhealth.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cardinalhealth.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cardinalhealth.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0000721371-22-000096-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000721371-22-000096-xbrl.zip
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MP@*JZ.+X](I<')^?75R]CF;L!.8\3]*<@FN?Q>22^QB<$MTD<4)T>YN])7%
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M#MG T'P]L(><ZI:U3GH1#2W@.YW0! #>OA'9),XS,J,)N:9ACCF%%VKVZ)#
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M/^%;O-FI-_;AC<]^_FGY<_.)*XDO?Q%,\C2&9X[^GU^.7QV?PR1W>S_]B$_
M_L'W^*\TESBY_/FG2:%(A3_I7^N!W;6E<EJI5:Q_"+BADL7+8"Z*BR1[/LFK
M*I^K>0?7D#E@.@<MA+9?KZWR]<G)QZ/3P_/CDP_!X;O3HZ-?CSZ<V[6LG^B?
MR[)*IBNU?4D6P\1?!(,]?-$]3/[9S^>SI 3&S1>R$%629\'A12$EG8*="C_[
MVW^-^_WNRXU;_R6SJ%',O%9Q KVV][(3!C$=15$&^30XDXM*(F\&HY!.5QC
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M%)+XIW<B((42#NY%TE9I\7J62">AXNBSC):DL)YP!DT87,UR]7JC,+^>B:1
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MS=LX6W"^6&+.FS8V^3MB+BZ4P5;(Q=+Z1'8.%>LK'1C3I-G*6*E\+KW^LDX
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M7DFF?5(]9.SDQVWU:=W[=J?U*WRC<,!.O59IK 7]P0 3S8C:.I7-]%OC[RN
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MYCJJ8Y89T+,IE^#+)#-A-1_5E6" +PC:NH'<0P%6-X_&03@T*;0V]JK3E G
M'Z_46"J,]DM,P$BFE+G-\/X3 J6EG!)Z2,Y%DH9.^-!^"E.BE&KJO&!L&OMY
M1J+ T;$G,LVON.Q?.E%3?$,@XIA ..I/[WAXHIU0(1)$,EDX$1Z=:].<>GT
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MX".?V3!XLS3%TZ>R7*#$(= Y1#E@:&)^LDFTA."*"Q9RA*.CF4=AF2F!&+A
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MU$!@@:\K.5=O^L54V1^54]TC?'YT\.C1HTAWJ6^CE.GCLZF-7[]8_2ERD)/
MD@ED[F;*\[2+);YPIVBF(S$U=0D>Q#.ZNB*S,.000_:>/^N?;]ZQ-L?Y?W_W
MZL6KM^*;;R8'S[Z@.Z!5&.<__B;VH'"=LA_D[T.+MIW#WR7HCTC)J;2E;F0M
MOE.R[BIQTC2F;PI,_-+<*MM(?!;G345_R9*<D$TIKBMI5849E!4_R[I7XI0,
M3)M&O&ITI_'Q5KEUUGZG>OV17//T1T)WF+L VR=EZ<2WIK<\TZNF5*W"?]"I
M,VU5T1GK@#2BJY1X82"B!\S*M\8N_"PO"-V4<^)'=:OQ_=0L%KKKE")6SF^Q
M3L! <65L-S.U-KR2/[3*\L+]HZOE\>@?8W!OBUUO\/_[9E]3][.?7ER\>C,2
M/U3:C,2U:KN)^'+D8?W33[X^/#@XCA"Q;AF?O?G;]?E1= ZG)]]]#K&6<@DQ
M>I,IA1YT7TC04@K9B=8X30(FQT/ZA%5I9;,$>5;4IIF/H1D+X?H"1@?BI[VN
M2[H7MK1& A/XU;$3K<4"F][5^</GUMR!S+:6C9N(MQ7P?H6@2MXJ,56-FFGR
MA#-K%OB][3L!A5>X)5P[KZ$;70>CP*B.O>>E;.!'^./%Y&H29? 9$72X?QQ&
M\+>#X\\GGWYR\.7^,2: >VH:6!/APIT&<=TZ5:/TN$I"9K4S@DV%A0FME9C"
M1!45<FZ5)X-G6Q//B!4Z(X9E==VI6X0&+Z2=8U1=BU^,;O*%2'>RH0LS&R!@
M\B!LX@0++FU'E.U2"*B1(9TIV.)90A">9\BJF56NXHLD(&)]15&3!K$ZC_B&
M#/P9[WO723QXJFO=+3-@ 4VX/2J$?R"M) 2(>PA2R_30X5?9MM:0PM%E? 'M
MGFA,-R-0;B >G8%R&5?D*%_/D;C4184X$'-;U8!<F'3_B^PJ*4[AL4HKG;J1
M5C9,PVEEM>N D.*R;\J;WD[$NTPI06ZI"2 S@K LNT3NN6&-FBJQD&620M\2
M'P=/!ST:B8,G=.VN@GW!<Z[P!EK@1;<I9.0ZNQWK@95H2CR;C/P.YG+/3,TS
MQQ6 3)PI<'Y=2#LUUO3SBJ7PO:D:\4[IFK[$.QD;,D6HE*:G=J"/7 ,I$TRY
MJ/M2A1\]^]#96TTZTC$#(#%HA+91&AE6J1H$TO2*/%97:2=F$O(C2EB0C>D\
M>PR.5HUY!%M^MW,A&+L1MO3XZ5(IDL4(8UU?LUA@[%(</!XO%$7!GNZ(4-^:
MNC9W$9C7Y_@-*P^A.(B?F'[ZY)&X,U :9N?P\2-A9:'!WE*8) S558TN^"(@
M0UD&0WS2)9[\0.#F_6PGF,8*L8-C6_6_%1$6/(;L#$=&I$^NAYD!U0CA%U"2
M"ND=1"*LO]FKT89)N ZN0,V7HZ1>,9H9B4*V%!1!&K4IO,.86;E0=\;>>-^0
M/(E+[DC,#5C%TQ;R7B_TKZ0,.]VN88/ #Z2>-#BX4QI/B@S=O0EAL7?![PG)
M(G(4E=3D[J: U4JKF3B_5T5/T"Q^F,U@7%9\+QUX^0[**A%#7@*WV)N!HRB%
MDYM*UV3:5ON)>8G(.A7%$4&2_LF>L&PQDBBD(V5FT-\A_EK-I;?7F2;O0+*0
MY:UV#'+\Y 5$,,"_3/A!T\UZW. M,!+!H9"Z;V'G$6;*OB!/!<N@  22IB K
M^.R9MHYBA7I&),*2Z!G)O  %CUFW*#T9?$XBWV.88Y+8*QE!CD@#U619<I0&
MAN:]+DD(#\,<0XSU3@4N2E'K&^4E*IL;#_()V(-B J C-.=9#!Q>G ;RF9,I
M84FR0;62I+N5;GE*R*NS>MIW26)WVK&N+!!0!ZT!C"VAR*X;A0 PKH:3NA0O
MK9H;W/ :_AFQ19YIG9+F0PA1V5+\M69_$[$N Q#?@E1?#A)WJH:VJ1 9#$'!
M$ RL>O]<(OS35-4:0U>B<X8+1"(+^I+;=31<;_@<,7O9+?0]$4^Z;#5YZH11
M[@9#O/P& =-:<"S IAK985M<#V&Q##/MG;]N1F%ELD!O%(!LC(6\(Z:&M&*
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MPF* P*?[3S^;?@X7.]60(LQ-!N?^YNQDJ.G$^93;YD$VH&P5S/X9?B2*-V:
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MA_#>TO\!4$L! A0#%     @ *S<F5<G > >A&@  )Z    \
M ( !     #(R+3DM-F-A:#AK+FAT;5!+ 0(4 Q0    ( "LW)E5N[.8 20,
M $@/   0              "  <X:  !C86@M,C R,C Y,#4N>'-D4$L! A0#
M%     @ *S<F5;:T96U_"   =%@  !0              ( !11X  &-A:"TR
M,#(R,#DP-5]L86(N>&UL4$L! A0#%     @ *S<F52K^1E;@!0  _#X  !0
M             ( !]B8  &-A:"TR,#(R,#DP-5]P<F4N>&UL4$L! A0#%
M  @ *S<F5?O+ 1/C40  A^T!  \              ( !""T  &5X:&EB:70Q
M,"TQ+FAT;5!+ 0(4 Q0    ( "LW)E6)_\KW'!D  ,!4   ;
M  "  1A_  !E>&AI8FET.3DM,7!R97-S<F5L96%S92YH=&U02P4&      8
,!@"% 0  ;9@

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
